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Mycobacterium tuberculosis (Mtb) is the etiological agent of tuberculosis, a disease 
that has plagued mankind for millennia and remains problematic today. Over 1.3 
million people died of tuberculosis in 2012, and many more remain latently infected 
with the potential to develop active TB. Although we have effective antibiotics, issues 
of drug resistance, lengthy treatment time, and drug side effects necessitate the 
development of novel therapies.  
Mtb, like other bacterial pathogens, depends on central carbon metabolic (CCM) 
pathways to generate energy and biosynthetic precursors, as well as to prevent buildup 
of toxic metabolites. These pathways provide a reservoir of potential drug targets, and 
growing evidence supports a role for CCM enzymes in growth and persistence of Mtb 
in vivo. However, there remains a paucity of information about the importance, 
function, and redundancy of specific enzymes. Here, we focused on studying the roles 
of two metabolic enzymes, fructose 1,6-bisphosphate aldolase (FBA) and malate 
synthase (MS), for Mtb growth, survival, and in vivo pathogenicity. 
Using conditional knockdown strains for FBA and MS, we found that both enzymes 
were essential for establishment and maintenance of infection within the mouse model. 
Interestingly, essentiality of both in vitro was dependent on the carbon source 
condition; FBA was essential for survival in media with single carbon sources whereas 
	  	  
MS was essential for survival in media with acetate or fatty acids. We also observed 
metabolic perturbations associated with exposure of MS and FBA knockouts to death-
inducing carbon sources, suggesting that death may be induced by metabolite 
imbalance or toxicity. Together, these data validate MS and FBA as drug targets worth 
pursuing and highlight the importance of recognizing that gene essentiality can be 
context-dependent.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Tuberculosis: A global health issue, past and present 
1.1.1  A brief history of tuberculosis 
“To him who follows her way, Nature reveals many roads that lead in the direction of 
truth.” ~René and Jean Dubos 
Tuberculosis (TB), consumption, “white plague”, and pthisis are all names for the 
disease caused predominately by the bacterium Mycobacterium tuberculosis (Mtb). 
With the limitation of having only the human species as a reservoir, Mtb cannot afford 
to kill its hosts before it has time to infect others. Mtb only causes active disease in 5-
10% of those infected at some point in their lifetimes (Russell, 2013). Those with 
active TB commonly experience a lung infection, with symptoms such as a persistent 
cough, blood in sputum, chest pain, fatigue, fever, and weight loss. In some cases, Mtb 
can cause disease in other parts of the body such as the brain, bones, bladder, liver, or 
spleen. TB does not usually lead to an immediate death even in those with active 
disease, which allows for transmission of the bacteria via aerosolized droplets 
generated through coughing.  
TB has been an enormous health burden to humans for millennia and is likely a 
product of a co-evolutionary relationship between bacterium and man. As of 2013, the 
oldest known human example of Mtb infection confirmed with DNA analysis is from 
the bones of a female and infant originating from Atlit-Yam, a now-submerged ancient 
settlement off the coast of Israel, dated 9250-8160 years ago (Anastasiou and Mitchell; 
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Hershkovitz et al., 2008). While Mycobacterium bovis from cattle has been postulated 
as an origin for Mtb during the advent of agriculture ~12,000 years ago, studies using 
whole genome sequencing analysis of various current Mtb strains support a history of 
Mtb-human co-evolution dating back to the movement of humans from Africa around 
50,000-70,000 years ago (Comas et al., 2013; Hershberg et al., 2008; Russell, 2013). 
However, the debate is ongoing, as another study suggests a 6,000 year-old origin for 
Mtb, based on mutation-rate analysis of DNA sequences from the bones of Peruvian 
mummies (Bos et al., 2014). If Mtb is really over 50,000 years old, perhaps it is not 
surprising that TB remains problematic despite modern medicine, considering the time 
Mtb has had to refine its relationship with its human host.  
Between the 17th and 19th centuries, approximately 1 in 5 people died of TB in North 
America and Europe (Comas et al., 2013). Therefore, it was of major significance in 
1882 when Robert Koch meticulously demonstrated that TB is caused by a 
transmissible agent, christened Mycobacterium tuberculosis (Dubos and Dubos, 1952). 
For the first time, an effort could be made to directly target the cause of TB by 
developing treatments that could kill the bacterium. In 1943 under the direction of 
Selman Waksman, Albert Schatz isolated the first effective antibiotic against TB. 
Working as a graduate student, Schatz isolated streptomycin from a soil microbe and 
confirmed its efficacy against a pathogenic tuberculosis strain. Within the next two 
decades, the antibiotics para-amino salicyclic acid, isoniazid, pyrazinamide, and 
rifampicin were also introduced as TB therapies (Zumla et al., 2013). This enabled 
combination therapy that reduced treatment time to 6 months. Unfortunately, complete 
TB eradication has proved more difficult than anticipated.   
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1.1.2  Current state of the tuberculosis pandemic 
In 2012, there were over 1.3 million deaths due to tuberculosis, putting TB among the 
15 leading causes of death worldwide (World Health Organization, 2012). Out of 
these deaths, 320,000 were cases of human immunodeficiency virus (HIV) co-
infection. HIV kills CD4+ T cells, a key component of the immune system important 
for containment of the infection. The World Health Organization has enacted a 
number of measures to improve diagnostics, health care, and treatment, which have 
contributed to a 45% drop in TB mortality rate from 1990-2012. The majority of TB 
cases are in South-east Asia, Africa, and the Western Pacific, where poverty and 
inadequate healthcare and diagnostics exhibit major barriers to TB eradication.  
Drug-resistance has also been a major barrier to TB eradication. Current frontline 
treatment for tuberculosis is a lengthy 6-month course of isoniazid, rifampicin, 
ethambutol, and pyrazinamide, which is successful in about 85% of new TB cases. 
Non-compliance with the required therapy as well as improper diagnosis of drug 
resistance has contributed to the emergence of multi-drug resistant (MDR)-TB (Müller 
et al., 2013). MDR-TB is defined as a resistance to rifampicin and isoniazid and is 
associated with longer therapy (with other, more toxic antibiotics) and poorer patient 
outcomes. In 2012, roughly 170,000 people died of multi-drug resistant (MDR)-TB, 
making the development of novel therapies of paramount importance.  
In late 2012, bedaquiline was approved by the Food and Drug Administration and 
became the first anti-tuberculosis drug in over 40 years to work via a novel 
mechanism of action (Zumla et al., 2013). Bedaquiline targets ATP synthase, an 
essential Mtb protein complex, and is now used to treat drug-resistant tuberculosis. A 
number of other anti-TB drugs remain in the pipeline and clinical trials (Lienhardt et 
al., 2012). While efforts are also ongoing to develop an effective vaccine, no attempt 
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has yet been successful. Novel compounds could provide alternative treatments to 
drugs that are no longer effective or which cause debilitating side effects, and 
potentially shorten the length of drug therapy. Therefore, efforts to develop new 
therapies remain a worthwhile investment.  
1.1.3  Target-based drug development: identification of essential genes 
Target-based drug design is a drug development approach in which pathways essential 
for viability are identified within Mtb prior to inhibitor testing. Once a target is 
identified, then high-throughput screening of compound libraries or structure-based 
drug design can be employed to generate compounds that inhibit the target (Payne et 
al., 2007). The sequencing and annotation of the complete Mtb genome enhanced our 
understanding of the potential targets in Mtb (Cole et al., 1998). Mtb has a 4.4 
megabase pair genome with ~4,000 genes. Of these, ~60% were assigned a putative 
function (Slayden et al., 2013). In order to assess the essentiality of these genes, a 
genome-wide transposon mutagenesis method was developed (Griffin et al., 2011; 
Sassetti et al., 2003; Zhang et al., 2012b). Genes that cannot tolerate insertions are 
predicted essential, and the most recent approach can determine specific genomic 
regions that are essential, regardless whether they lie within or adjacent to a gene 
(Zhang et al., 2012b). However, there are caveats associated with these approaches, as 
mutants are always pooled together and must pass through growth stages in vitro that 
vary from the environment in vivo. Genetic studies involving deletion or conditional 
expression of specific genes are necessary to confirm whether these genes are essential 
and under which context. As with most research, the environment of utmost 
importance is the human host, in which it is not possible to study the impact of 
introduced Mtb gene mutations. Instead, the pathogenesis of Mtb mutants is 
determined using in vitro conditions and animal models that attempt to mimic the host 
	  	  5 
environment. Despite the limitations of these models, they contribute extensively to 
our understanding of Mtb biology.  
1.2 Context of infection: Mtb adaptation to host environments 
1.2.1  Introduction to the bug: Mycobacterium tuberculosis  
Mtb is a rod-shaped bacterium 3-4µm in length whose structure consists of a 
cytoplasm encased by a complex and specialized cell envelope (Fattorini et al., 2013). 
In order from inside to outside, this is comprised of an inner phospholipid bilayer 
plasma membrane, a cell wall “core” with covalently-linked peptidoglycan-
arabinogalactan-mycolic acids containing free intercalated lipids and lipoglycans, and 
a capsule consisting of proteins, polysaccharides, and small amounts of lipids (Hett 
and Rubin, 2008; Jackson, 2014; Sani et al., 2010). Detergent, such as Tween® 80 or 
tyloxapol, is required to prevent clumping in liquid culture and can lead to loss of the 
capsule layer in Mycobacterial species (Sani et al., 2010). The mycolic acids and 
freely-linked lipids are referred to as the outer membrane or “mycomembrane,” a non-
conventional bilayer. Between the outer membrane and inner membrane exists a 
periplasmic space. Therefore, Mtb shares characteristics with both Gram-positive and 
Gram-negative bacteria but possesses a waxy cell wall not found in either of these 
classes, making it uniquely resistant to certain antibiotics (Jackson, 2014). 
Components of this cell envelope not only protect the bacteria but also dictate the 
immune response of the host to Mtb by modulating the host response and inducing 
recruitment of specific macrophage populations (Cambier et al., 2014). 
Mycobacterium tuberculosis shares a genus with the causative agent of leprosy, 
Mycobacterium leprae, as well as with members of the Mycobacterium tuberculosis 
complex (MTBC) such as M. canetti, M. bovis, M. africanum, and M. microti. 
Members of the MTBC can also cause tuberculosis, but do so much less frequently 
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than Mtb. The bacterium M. smegmatis is also a close relative. Unlike Mtb, this 
organism is less pathogenic and faster-growing than Mtb and therefore is often studied 
as a surrogate for Mtb. Also, comparisons with Corynebacterium glutamicum, a more 
distant relative, are useful as this organism’s metabolism has been extensively studied 
and engineered for industrial production of metabolic compounds. The genome of Mtb 
is ~4,411 kilobases, while the genome of M. smegmatis is ~6,988 kilobases. M. leprae 
has the smallest genome of the MTBC, at ~3,268 kilobases.  
Work with Mtb is challenging for several reasons. Mtb can be cultured in vitro, but 
divides very slowly in media optimized for its growth. Wild type Mtb has a generation 
time of ~24 hours and takes ~2½ weeks to form colonies on plate media. Work with 
pathogenic Mtb strains must be carried out in a biosafety level 3 (BSL3) facility, 
although Mtb DNA and protein lysates can be removed after sterilization. Options are 
limited for microscopy, as bacteria must be formalin-fixed prior to removal from the 
BSL3 facility, or the microscope must reside within the BSL3 facility. Animal models 
such as guinea pigs, non-human primates, rabbits, and mice have been used to mimic 
the course of Mtb infection. Mice are commonly used as they are less expensive than 
other models, easier to handle, and readily available, but they have significant 
differences compared to human infection in terms of lung lesion composition and the 
level of bacterial burden throughout infection. 
1.2.2  Human infection with Mtb 
Infection with Mtb begins with inhalation of an infectious particle, containing live 
bacteria. Bacteria are internalized by phagocytic cells lining the airways (Stallings and 
Glickman, 2010). Activation of the adaptive immune response follows trafficking of 
Mtb to the lymph nodes either by dendritic cells or entrance into the blood stream. 
This results in the recruitment of lymphocytes to the lung, such as CD4 T cells. These 
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cells secrete interferon gamma (IFNγ), a cytokine critical for macrophage activation. 
Activation of the adaptive immune response is required for containment and reduction 
of bacterial burden, but it does not eradicate all bacteria. Following initial infection, 
most patients enter into latent infection, in which they display no symptoms, but 
harbor a population of viable bacteria that for ~5-10% of people will reactivate at 
some point in their lifetime (Russell, 2013). At this point of active infection, bacteria 
may be coughed up with sputum and become airborne, ready to infect the next person.  
Although Mtb can disseminate to regions throughout the body, it manifests primarily 
in the lung. Mtb induces the formation of granulomas, walled-off structures consisting 
of host cells (macrophages, surrounded by CD4 and CD8 T cells, B cells, neutrophils, 
epitheloid macrophages, multinucleated giant cells, fibroblasts, and dendritic cells) 
necrotic cell debris, cytokines, fibrosis (extracellular matrix), and bacteria (Tufariello 
et al., 2003). Granulomas are heterogeneous even within the same person, and may be 
fibrotic (consisting mainly of fibroblasts), caseous (containing a necrotic center with a 
cottage cheese-like consistency), or non-necrotizing (solid, consisting largely of 
macrophages) (Barry et al., 2009).  
Mtb is an established intracellular pathogen and macrophage infection is a central 
component of Mtb pathogenesis. Mtb employs a wide variety of mechanisms to 
survive within macrophages, a cell type whose primary function is to kill invading 
pathogens. After phagocytosis by resting macrophages, Mtb exists within membrane-
bound compartments called phagosomes and prevents their acidification my 
modulating the host response with glycolipids and secreted proteins (Russell et al., 
2010). Upon IFNγ-mediated macrophage activation, Mtb is able to maintain 
intrabacterial pH despite phagosome acidification (Vandal et al., 2009). Alongside 
acid stress, Mtb must also survive exposure to reactive oxygen species, reactive 
	  	  8 
nitrogen species, nutrient limitation, and hypoxia. The mechanisms by which Mtb 
survives these stresses are the focus of active and ongoing research. 
In addition to the macrophage phagosome, other host environments are habitable for 
Mtb. Mtb has been shown to infect cell types other than macrophages, including 
neutrophils and dendritic cells. There is some evidence that Mtb can enter the cytosol 
of infected cells (van der Wel et al., 2007). Extracellular survival may also be critical 
to Mtb pathogenesis. Mtb have been shown to form biofilm-like structures in vitro, 
which consist of clusters of bacteria held together by secreted mycolic acids (Ojha et 
al., 2008). In guinea pigs, bacteria have been observed by acid-fast staining in clusters 
around primary lesions (Orme, 2014). Mtb may be exposed to hypoxic stress while in 
areas like these, or while in the extracellular environment of the caseum. In summation, 
Mtb bacilli are exposed to a wide range of environments within a person over the 
course of infection, and Mtb must be able to survive within these environments.  
1.2.3  Bacterial persistence 
After establishment of infection and activation of the adaptive immune system within 
the host, bacterial numbers often decrease. This is termed the latent infection, in which 
no clinical symptoms are present. During this phase, infection is contained within 
granulomas, and bacteria cannot be cultivated from blood or sputum samples. 
Surviving Mtb is thought to exist in mixed populations of growing and dormant/slow-
growing bacteria that are dynamic, depending on the environment (Esmail et al., 2012). 
This is one reason why the lengthy 6 month or longer drug therapy regimen may be 
necessary, as these slow-growing or dormant cells are resistant to antibiotics. The 
antibiotic pyrazinamide is unusual in that it is more effective against slower-growing 
cells than rapidly dividing cells and thus plays a role in shortening Mtb therapy (Zhang 
et al., 2012a). However, killing of a persistent population also depends on the ability 
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of a drug to access the target, which may differ depending on the type of granuloma 
and the localization of the bacteria (Fattorini et al., 2013). Furthermore, there may be 
subpopulations of persistent cells, each with differential susceptibility to antibiotics.   
The definition of a “persister” is a bacterial cell that survives a cidal dose of antibiotics, 
but does not differ genetically from susceptible cells (Bigger, 1944; Girgis et al., 2012; 
Zhang et al., 2012a). This definition does not explain how the persister developed, nor 
does it define whether this persister has specific requirements for subsequent culture 
or is metabolically active. Further terms like “viable but non-culturable (VBNC)” or 
“non-growing but metabolically active (NGMA)” have been used to describe Mtb 
populations that do not grow on agar plates and are therefore non-detectable via 
colony-forming unit (CFU) counts, but can still “reawaken” at a later time, multiply, 
and cause disease. This is evidenced by the presence of a bacterial population that is 
not represented in CFU counts of human sputum samples (Mukamolova et al., 2010). 
Culture of this population is enabled by addition of supernatant of actively dividing 
bacteria, which contains Mtb resuscitation promoting factors, and perhaps other 
factors that stimulate bacterial growth (Mukamolova et al., 2010). 
It is worth distinguishing the term of “persister” from the definition of persistence in 
the mouse model. In mice, bacterial burden increases for the first three weeks post-
infection and then plateaus, as measured by CFU. This is termed a chronic infection, 
as there is little reduction in bacterial numbers for over 4 months, although a study 
using a clock plasmid concluded that bacteria are dividing and dying throughout this 
period (Gill et al., 2009). Here, this can be termed a persistent population, but the 
majority are not “persisters,” because they are susceptible to antibiotics. The Cornell 
model, in which mice are infected with Mtb and treated with antibiotics until there are 
no detectable CFU, demonstrated the presence of a paucibacillary persister population 
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in mice. This was evidenced by the reappearance of a detectable bacterial population 
by CFU after the removal of antibiotics, which was exacerbated by immune 
suppression (McCune et al., 1966). The genes and pathways required for 
existence/generation of this VBNC or NGMA bacterial population remain to be 
determined. 
How might such persister or slow-growing bacteria arise? Mycobacteria have been 
shown to exist in a heterogeneous population in the absence of stress. Mycobacteria 
divide asymmetrically, which contributes to a subpopulations of cells with differential 
growth-rates and susceptibility to antibiotics (Aldridge et al., 2012). Examination of 
single mycobacterial cells using a microfluidic device has revealed stochastic 
expression of enzymes such as KatG, which is critical for activation of the drug 
isoniazid (Wakamoto et al., 2013). Studies identifying persisters in bacterial 
populations did not expose the bacteria to stress prior to antibiotic treatment (Girgis et 
al., 2012). However, host stresses and antibiotics have been shown to induce a slow 
down of growth rate. Mtb encodes multiple stress response pathways, such as the 
DosR regulon, which is induced under hypoxic stress. Importantly, adaptations in 
carbon metabolic pathways have also been linked to establishment and maintenance of 
slow-growing bacterial populations (Baek et al., 2011; Eoh and Rhee, 2013; 
Gengenbacher et al., 2010; Rodriguez et al., 2014).  
In Mtb, ability to slow down metabolism has been linked with drug-tolerance. 
Hypoxia is a stress present in the human host and is known to trigger a metabolic 
slow-down of Mtb in vitro, which is dependent on the presence of a triacylglycerol 
(TAG) synthase encoded by tgs1 in Mtb (Baek et al., 2011). Deletion of tgs1 or 
overexpression of citA (a gene encoding citrate synthase) increases the flux of acetate 
through the TCA cycle by preventing acetyl-CoA rechanneling into TAG or by 
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increasing the incorporation of acetyl-CoA into the TCA, respectively. These mutants 
also do not slow down growth in response to hypoxia or low iron stresses and are less 
resistant to antibiotics in vitro and in the mouse model (Baek et al., 2011; Deb et al., 
2009). Therefore, metabolic activity of the TCA cycle may be closely linked with Mtb 
cell growth and antibiotic susceptibility. In summation, it is relevant to consider the 
carbon sources available to Mtb while in the host, whether adaptation to these carbon 
sources could contribute to the emergence of a latent Mtb population, and whether 
targeting metabolic pathways could be a viable strategy to kill latent bacteria. 
1.2.4  Carbon source availability to Mtb within the host 
Lipids, including fatty acids, can be used as carbon sources by Mtb. There is much 
evidence to support an abundance of lipids both within host macrophages and 
extracellular within the granuloma. Lipids identified within the caseum of tuberculosis 
granulomas include cholesterol ester, cholesterol, triacylglycerol (TAG), and 
lactosylceramide (Kim et al., 2010). Transcriptional profiling of caseous human lung 
granulomas identified upregulation of human genes involved in lipid metabolism (Kim 
et al., 2010).  Lung surfactant is taken up my alveolar macrophages and contains fatty 
acids such as dipalmitoyl phosphatidylcholine (Muñoz-Elías and McKinney, 2006). 
Within a macrophage, lipids can be derived from the phagosomal membrane. 
Furthermore, the macrophages in which Mtb bacilli are chiefly found are abundant 
with lipid-rich bodies. These cells are termed foamy macrophages and are only present 
within tuberculous lesions. Foamy macrophages were shown to be induced by Mtb 
lipids in vitro, and Mtb-containing phagosomes within these macrophages migrated to 
merge with lipid bodies (Peyron et al., 2008; Russell et al., 2009). Another study 
showed that hypoxia also induced lipid droplet formation within human THP-1 
macrophages and peripheral-blood monocyte-derived macrophages, and that Mtb 
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imported and metabolized fatty acids derived from macrophage TAG (Daniel et al., 
2011). 
Studies of the Mtb response to host and host-like environments further support a 
bacterial diet high in lipids. Early studies highlighted that Mtb harvested from human 
sputum samples is adapted for life on fatty acids but not carbohydrates (Segal and 
Bloch, 1956). Mtb from sputum samples was also shown to have high levels of TAG 
and upregulation of transcripts of the DosR regulon (Garton et al., 2008). Mtb has 
extensive duplication of genes encoding enzymes involved in β-oxidation, a major 
fatty acid catabolic pathway (Cole et al., 1998). Mtb also encodes genes for lipid 
transporters, including cholesterol transporters. Also, transcriptional upregulation of 
genes involved in fatty acid utilization pathways has been observed in Mtb harvested 
from macrophages and mice (Rohde et al., 2012; Schnappinger et al., 2003; Shi et al., 
2010). Genetic studies, which will be mentioned later, highlight the importance for 
fatty acid metabolic pathways for establishment and maintenance of infection within 
mice (Marrero et al., 2010; McKinney et al., 2000; Pandey and Sassetti, 2008). Taken 
together, these data suggest that Mtb is likely to encounter and metabolize lipids 
within the host environment, and that lipid metabolism is important for Mtb virulence. 
However, lipids may not be the only carbon source available for Mtb in the host. 
Metabolomic 13C-flux spectral analysis of Mtb-infected human THP-1 macrophages 
supported a role for alanine, serine, glutamate, aspartate and CO2 as carbon sources for 
Mtb during infection in addition to lipids. Metabolomic profiling of guinea pig lung 
granulomas over the course of Mtb infection by nuclear magnetic resonance 
spectroscopy (NMR) indicated an increase over time in aspartate, lactate, alanine, 
acetate, and glutamate, among other metabolites (Somashekar et al., 2011). 
Furthermore, Mtb lacking glucokinases, enzymes involved in utilization of 
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carbohydrates, were impaired in ability to persist in mice (Marrero et al., 2013). These 
studies suggest that Mtb faces a wide variety of carbon sources in vivo, but perhaps not 
simultaneously. But how does Mtb use these carbon sources and what is known about 
metabolic pathways in Mtb? This will be the focus of the following section.  
1.3 Carbon metabolic pathways in Mtb and other bacteria 
1.3.1  Overview of carbon metabolic pathways 
All organisms on earth are “carbon-based” and require carbon metabolic pathways for 
growth and survival. Without them, food (in this case, a carbon-containing compound) 
cannot be converted into energy and building blocks for cells within the organism 
(Table 1.1). Carbon metabolic pathways are critical for the generation of adenosine 
triphosphate (ATP), a high-energy bond-containing molecule used as energy currency 
within the cell, as well as reduced nicotinamide adenine dinucleotide (NADH), which 
donates electrons into the electron transport chain to generate the proton motive force 
required for ATP generation. Enzymes, usually proteins, are catalysts that increase the 
rate of pathway reactions by lowering their activation energies. Enzymes of carbon 
metabolic pathways such as glycolysis and the tricarboxylic acid (TCA) cycle are 
conserved not only between different animal phyla, but between domains as well. The 
directionality of enzymatic reactions depends on the energetic favorability of the 
reaction or downstream reactions, their reaction mechanism, and the concentrations of 
substrate and product. Due to these reasons, some enzymes are unidirectional.  
Mtb encodes homologs of enzymes in many of the known bacterial metabolic 
pathways, although many of these lack functional confirmation through biochemical, 
metabolomic, or gene deletion studies. This section will describe major carbon 
metabolic pathways known in bacteria before focusing on metabolism in Mtb 
specifically. 
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Table 1.1. Contributions of carbon metabolic pathways to biosynthetic precursor 
generation.  
Metabolite precursor Required for  Pathway 
Ribose-5-phosphate Nucleic Acids PPP 
Erythrose-4-phosphate Amino Acids PPP 
Glucose-6-phosphate Polysaccharides  Glycolysis/Gluconeogenesis 
Fructose-6-phosphate Cell wall peptidoglycan Glycolysis/Gluconeogenesis 
Triose-phosphate Lipids Glycolysis/Gluconeogenesis 
3-phosphoglycerate Amino Acids Glycolysis/Gluconeogenesis 
Phosphoenolpyruvate Amino Acids Glycolysis/Gluconeogenesis 
Pyruvate Amino Acids Glycolysis/Gluconeogenesis 
Acetyl-CoA Fatty Acids TCA cycle 
α-ketoglutarate Amino Acids TCA cycle 
Succinyl-CoA Amino Acids TCA cycle 
Oxaloacetate Amino Acids TCA cycle 
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Glycolysis and gluconeogenesis 
Glycolysis (also known as the Embden-Meyerhof-Parnas or EMP pathway) is a series 
of enzymatic steps that result in the formation of pyruvate from glucose (Kim, 2008). 
During glycolysis, two molecules of NADH and pyruvate are generated, as well as 
two molecules of ATP via substrate level phosphorylation for every glucose molecule. 
Important metabolites generated in addition to pyruvate are glucose-6-phosphate, 
which feeds into the pentose phosphate pathway to generate NADPH and nucleic acid 
precursors, and fructose-6-phosphate, which feeds into peptidoglycan synthesis. Also, 
triose phosphates are precursors for lipid biosynthesis, while 3-phosphoglycerate and 
pyruvate are precursors for amino acids. Pyruvate can also be converted to acetyl-CoA 
by the pyruvate dehydrogenase complex (pyruvate + coenzyme A + NAD+ to acetyl 
CoA + NADH + H+). Acetyl-CoA can then participate in the TCA cycle, fatty acid 
biosynthesis, or branched chain amino acid biosynthesis.  
Gluconeogenesis is the series of enzymatic steps resulting in the generation of 
glucose-6-phosphate, glucose, or glycogen from non-carbohydrate carbon sources. 
Many of the enzymes that participate in glycolysis also can function in the opposite 
direction in gluconeogenesis. Since many steps are the reverse of glycolysis, ATP is 
used rather than generated for these reactions to proceed.  
Enzymes that only participate in glycolysis and not gluconeogenesis are 
phosphofructokinase (converts fructose-6-phosphate to fructose-1,6-bisphosphate) and 
pyruvate kinase (phosphoenolpyruvate +ADP to pyruvate +ATP). Enzymes that 
participate in gluconeogenesis but not glycolysis include those involved in PEP 
synthesis and fructose bisphosphatase (converts fructose-1,6-bisphosphate to fructose-
6-phosphate). PEP synthesis can be achieved through the action of 
phosphoenolpyruvate synthetase (pyruvate + ATP to PEP + AMP + Pi), pyruvate-
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phosphate dikinase (pyruvate + ATP +Pi to PEP + AMP +PPi), or 
phosphoenolpyruvate carboxykinase (oxaloacetate + ATP to PEP + CO2 +ADP). 
Malic enzyme can generate pyruvate directly from malate (malate + NAD+ + H+ to 
pyruvate + NADH + CO2). Oxaloacetate decarboxylase can convert oxaloacetate to 
pyruvate and CO2. 
To prevent futile cycling (waste of ATP due to pathways going in both directions 
within the same cell), many bacteria have regulatory mechanisms that drive 
metabolism in either the glycolytic or gluconeogenic direction. This can involve 
transcriptional/translational control of enzyme expression, post-translational 
modifications of enzymes, or allosteric regulation of enzymes by the levels of 
metabolites within the pathways or coenzymes such as ATP.  
Pentose phosphate pathway 
The pentose phosphate pathway, or hexose monophosphate (HMP) pathway, uses 
glucose-6-phosphate to generate NADPH and biosynthetic precursors such as ribose-
5-phosphate (nucleic acid synthesis) and erythrose-4-phosphate (amino acid synthesis). 
NADPH can help maintain redox homeostasis by being a source of reducing power 
(Hasan et al., 2010). Other metabolic products include glyceraldehyde 3-phosphate 
and fructose-6-phosphate, which participate in glycolysis and gluconeogenesis. 
Therefore, the pentose phosphate pathway can act as a potential inefficient bypass of 
several enzymatic steps in glycolysis.  
Entner-Doudoroff pathway 
Some bacteria, such as Pseudomonas species and E. coli, have an Entner-Doudoroff 
pathway, which acts alongside or replaces glycolysis. In the ED pathway, glucose is 
converted into glucose-6-phosphate, which is converted into 6-phosphogluconate, 
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which is dehydrated to form 2-keto-3-deoxyphosphogluconate. This metabolite is split 
into glyceraldehyde-3-phosphate (G3P) and pyruvate. G3P can then go through the 
same enzymatic steps as in glycolysis to generate pyruvate. Therefore, the net gain is 
one ATP, one NADH, and one NADPH per glucose metabolized in this pathway.  
Methylglyoxal bypass 
An alternative to the glycolytic steps converting dihydroxyacetone phosphate to 
pyruvate is the methylglyoxyal bypass pathway. This removes the requirement for 
phosphate, but involves the formation of methylglyoxyal, a highly reactive compound 
that can damage nucleic acids and proteins. Methylglyoxyal toxicity is controlled by 
secretion and by glyoxylases, enzymes that converts methylglyoxal to D-lactate, 
which is then converted to pyruvate by lactate oxidase.  
Tricarboxylic Acid cycle 
The tricarboxylic acid cycle (TCA), also known as the Kreb’s cycle or citric acid cycle, 
oxidizes the carbon from acetyl-CoA to generate CO2, which also produces NADH, 
NADPH (or another NADH, depending on the type of isocitrate dehydrogenase 
present), and ATP. Further reactions within the TCA cycle generate FADH2, and one 
more NADH. These cofactors can then donate electrons into the electron transport 
chain, resulting in the synthesis of ATP.  
Because of the output of two CO2 molecules in the TCA cycle, there is no net gain of 
carbon with entrance of acetyl-CoA, a two-carbon molecule. However, metabolites in 
the TCA cycle also are biosynthetic precursors for amino acids, so bacteria must have 
alternative ways of replenishing these metabolites. One way is to generate 
oxaloacetate from either PEP or pyruvate, with incorporation of CO2. This is catalyzed 
by pyruvate carboxylase (pyruvate + HCO3- + ATP to oxaloacetate + ADP + Pi) or 
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PEP carboxylase (PEP + HCO3- to oxaloacetate + Pi). Phosphoenolpyruvate 
carboxykinase, although noted for its role in gluconeogenesis, can also convert PEP to 
oxaloacetate (PEP+HCO3-+GDP to oxaloacetate+GTP). 
The TCA cycle contains one enzymatic reaction that is part of the electron transport 
chain, which is the conversion of succinate and FAD to fumarate and FADH2 by 
succinate dehydrogenase. This enzyme is part of a multi-unit complex, in which at 
least one subunit is membrane-bound. Electrons pass directly from succinate into the 
electron transport chain. 
Metabolites in the TCA cycle feed into amino acid biosynthesis. α-ketoglutarate 
contributes to glutamate, glutamine, arginine, and proline synthesis; oxaloacetate 
contributes to aspartate, asparagine, methionine, lysine, isoleucine, and threonine 
synthesis.  
Glyoxylate pathway (shunt) 
When bacteria grow on fatty acids, these are converted to acetyl-CoA, which cannot 
feed directly into PEP or pyruvate. Furthermore, the two carbons from acetyl-CoA are 
lost following the canonical TCA cycle. Therefore, an alternative anapleurotic 
pathway is required in order for carbon to be retained as biomass. This is termed the 
glyoxylate pathway (shunt or bypass), because glyoxylate is an intermediate. This 
pathway consists of two steps: the cleavage of isocitrate to glyoxylate and succinate by 
isocitrate lyase and the conversion of glyoxylate and acetyl-CoA to malate and CoA 
by malate synthase.  
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Methylcitrate pathway 
The methylcitrate pathway is a way for bacteria to detoxify propionyl-CoA derived 
from odd-chain fatty acids, as well as to grow on odd-chain fatty acids. It begins with 
the condensation of propionyl-CoA and oxaloacetate to form methylcitrate catalyzed 
by methylcitrate synthase. The following steps ultimately result in the formation of 
pyruvate and succinate. This pathway is remarkably similar in its enzymatic steps to 
the TCA/glyoxylate cycle conversion of oxaloacetate and acetyl-CoA to succinate and 
glyoxylate.  
Methylmalonyl pathway 
The methylmalonyl pathway is an alternative to the methycitrate cycle as a propionyl-
CoA detoxification pathway, and is also involved in lipid synthesis. The first step 
converts HCO3-, ATP, and propionyl-CoA to (S)-methylmalonyl CoA, a phosphate, 
and ADP with the enzyme propionyl-CoA carboxylase. This product is converted to 
(R)-methylmalonyl-CoA by racemase, which is then converted to succinyl-CoA and 
pyruvate by methylmalonyl-CoA mutase, a vitamin B12-dependent enzyme. These 
products can then feed into the TCA cycle and acetyl-CoA production. 
Methylmalonyl-CoA contributes to synthesis of methyl-branched fatty acids. 
β-oxidation 
β-oxidation is a series of enzymatic steps by which odd-chain (5 carbon or longer) or 
even-chain fatty acids (4 carbon or longer) gain CoA and are broken down and 
converted into acetyl-CoA, with one molecule of propionyl-CoA for odd-chain fatty 
acids. During this process, ATP is used while FADH2 and NADH are generated. 
Therefore, this pathway has the potential to increase the reductive stress a cell faces, 
but also feeds into the TCA cycle and propionyl-CoA metabolic pathways.  
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1.3.2 Understanding metabolism in Mtb  
Carbon metabolic pathways in Mtb are less well studied compared to those in other 
bacteria such as Escherichia coli or Corynebacterium glutamicum. Although these 
organisms, especially the more closely-related C. glutamicum, are useful reference 
points for Mtb metabolic pathways, research has revealed differences compared to the 
metabolic pathways of Mtb. Therefore, it is worthwhile exploring the following 
questions about Mtb specifically: 
First, what pathways exist by gene annotation? What have subsequent studies on 
specific genes revealed about their function? Which carbon sources can Mtb use for 
growth and how does Mtb do this? Finally, what evidence do we have to implicate 
specific pathways in pathogenesis?  
1.3.2.1 Gene annotation of metabolic pathways 
Mtb has genes annotated to encode enzymes for glycolysis, gluconeogenesis, the 
pentose phosphate pathway, the TCA cycle, the methylcitrate cycle, the 
methylmalonyl pathway, and the glyoxylate pathway (Figure 1.1) (Cole et al., 1998). 
Mtb lacks homologs for the Entner-Doudoroff pathway. Furthermore, Mtb contains 
many gene homologs for β-oxidation enzymes, suggesting an important role for fatty 
acid breakdown for Mtb pathogenesis. However, ~40 percent of open reading frames 
encode hypotheticals or genes of unknown function, leaving the possibility of the 
presence of undiscovered metabolic enzymes (Slayden et al., 2013). 
Despite the usefulness of gene annotation, genetic, metabolomics, and biochemical 
studies are necessary to confirm the functions of specific genes and the absence of 
genes with similar functions. For example, glucokinase is an enzyme that  
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Figure 1.1. Carbon metabolic pathways in Mtb. (Figure from Rhee et al., 2011) 
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phosphorylates glucose as the first committed step of glycolysis. An Mtb knockout 
lacking the only predicted glucokinase gene ppgK had impaired but not abolished 
growth on glucose (Marrero et al., 2013). However, a double knockout lacking both 
ppgK and rv0650 (annotated as a “possible sugar kinase”) was unable to grow in 
glucose entirely and exhibited a persistence defect in the mouse.  
Conversely, in some cases a gene has a predicted function but genetic studies fail to 
support it. Mtb encodes two predicted phosphofructokinases, pfkA and pfkB. However, 
knockout of pfkA alone was enough to abolish growth on glucose, while knockout of 
pfkB did not have an effect on growth in glucose (Phong et al., 2013). Furthermore, the 
pfkB knockout exhibited PFK activity in vitro, wheras the pfkA knockout did not. The 
pfkA knockout was not impaired in ability to infect and persist in the mouse model, 
suggesting that either PFK is not essential for mouse infection, that pfkB is active in 
vivo, or that there is an alternative gene that compensates for loss of pfkA that may be 
expressed during infection.  
Another example of non-predictability in Mtb carbon metabolic pathways is manifest 
in the TCA cycle conversion of α-ketoglutarate to succinate (Figure 1.2). 
Metabolomics analysis has suggested a partial bifurcation of the TCA cycle, as there is 
lack of clear flux from α-ketoglutarate to succinate (de Carvalho et al., 2010a). 
However, Mtb expresses several enzymes that can catalyze the generation of succinate 
from α-ketoglutarate. The enzyme encoded by Rv1248c can act as a subunit of α-
ketoglutarate dehydrogenase, as well as exhibits 2-hydroxy-3-oxoadipate synthase and 
thiamine diphosphate-dependent α-ketoglutarate decarboxylase activity. α-
ketoglutarate dehydrogenase complex converts α-ketoglutarate to succinyl-CoA, 
which can then be converted to succinate via succinyl-CoA synthetase. The existence  
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Figure 1.2. Enzymatic reactions involving α-ketoglutarate in Mtb. KGD, α-
ketoglutarate decarboxylase; HOAS, 2-hydroxy-3-oxoadipate synthase; KOR, α-
ketoglutarate ferridoxin oxidoreductase; KDH, α-ketoglutarate dehydrogenase 
complex. (Figure from Ehrt and Rhee, 2013) 
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of this enzymatic activity was thought to be absent, but has been demonstrated more 
recently (Tian et al., 2005; Wagner et al., 2011). 2-hydroxy-3-oxoadipate synthase 
(HOAS) converts α-ketoglutarate and glyoxylate to 2-hydroxy-3-oxoadipate, which 
can potentially detoxify glyoxylate or feed into alternative metabolic pathways (de 
Carvalho et al., 2010b). Thiamine diphosphate-dependent α-ketoglutarate 
decarboxylase catalyzes the decarboxylation of α-ketoglutarate to succinic 
semialdehyde, which through the actions of succinic semialdehyde dehydrogenases 
GabD1 and GabD2 can be converted to succinate with the concomitant production of 
NADPH (Tian et al., 2005). Furthermore, the existence of α-ketoglutarate ferridoxin 
oxidoreductase (KOR) provides an alternative pathway for conversion of α-
ketoglutarate to succinyl-CoA (Baughn et al., 2009). The gene encoding a probable 
succinyl-CoA synthetase, sucC, is one of the most abundant proteins expressed in Mtb, 
suggesting that conversion of succinyl-CoA to succinate may be an important 
enzymatic step (Schubert et al., 2013). These studies highlight the potential for 
unforeseen complexity in Mtb metabolic pathways and the need for biochemical, 
metabolomic, and genetic studies to validate gene annotations.    
1.3.2.2 Mtb uptake and metabolism of specific carbon sources 
Early studies found that Mtb can grow on a variety of carbon substrates, as indicated 
by oxygen consumption (Edson, 1951). Here, entrance of specific carbon sources into 
the cell and their utilization are discussed. 
Carbohydrates 
While M. smegmatis expresses many putative sugar transporters, Mtb only expresses 
genes for four ABC-type transporters and one sugar permease (Niederweis, 2008). M. 
smegmatis also expresses genes for a phosphotransferase system (PTS) which is 
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involved in carbon catabolite repression. This is a system by which carbon source 
regulates activity of specific metabolic pathways, and by which an organism can 
preferentially use one carbon source over another. Mtb lacks genes for this system 
(Titgemeyer et al., 2007). Currently, it is known that Mtb can grow on glucose, but the 
specific transporters required for glucose entry past the inner membrane have not been 
elucidated. Furthermore, carbohydrates may also require a porin to traverse the outer 
membrane, but this has not been elucidated (Niederweis, 2008). Within the cell, 
glucose can be phosphorylated by glucokinases to form glucose-6-phosphate, entering 
into glycolysis.  
Trehalose, a disaccharide, can also be used as a sole carbon source for Mtb growth. 
One of the putative sugar transporters, the ABC transporter LpqY-SugA-SugB-SugC, 
has been shown to act as a trehalose transporter (Kalscheuer et al., 2010). Trehalose 
accounts for 1.5-3% of dry weight of M. smegmatis cultured in vitro and is 
incorporated into mycobacterial glycolipids (Smet et al., 2000). Conversely, trehalose 
levels in mammals are thought to be low, because mammals express trehalase, an 
enzyme that hydrolyzes trehalose to glucose. Therefore, it is doubtful that trehalose 
coming from the host would be sufficient to support Mtb growth and it is more 
probable that trehalose is recycled by Mtb during host infection (Kalscheuer et al., 
2010).  
Glycerol and Triglycerides/Triacylglycerol (TAG) 
Glycerol is 3-carbon molecule with three hydroxyl groups and is a common 
component of Mtb culture media due to its ability to enhance growth of Mtb. Glycerol 
has been shown to diffuse through lipid membranes so therefore may not require a 
specific transporter (Niederweis, 2008). However, the outer membrane porin protein 
CpnT was recently demonstrated to play a role in glycerol uptake, and deletion of the 
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gene encoding CpnT in Mtb resulted in a growth delay compared to the wild type 
strain in glycerol (Danilchanka et al., 2014). Glycerol is converted to glycerol-3-
phosphate by glycerol kinase (glpK) and then dihydroxyacetone phosphate (DHAP) by 
glycerol-3-phosphate dehydrogenase. DHAP can enter into either glycolysis or 
gluconeogenesis.  
Triacylglycerol (TAG) is an ester composed of glycerol and three long-chain fatty 
acids. Mtb generates TAG during exposure of Mtb to stress conditions such as hypoxia 
and low pH, and Mtb extracted from host lesions have been shown to contain TAG 
inclusion bodies (Garton et al., 2002; Sirakova et al., 2006). Mtb may use this 
intracellular TAG store as a carbon source, and also has been shown to incorporate 
TAG-derived carbon from the host into its own TAG (Daniel et al., 2011). Mtb 
expressed LipY, a TAG hydrolase, that could be involved in the breakdown of TAG 
for use as a carbon source by the bacillus (Mishra et al., 2008). 
Acetate and Propionate 
Acetate, a two-carbon carboxylate ion, is thought to freely permeate through bacterial 
membranes, and no acetate transporter has been identified in Mtb. Mtb can grow with 
acetate as a sole carbon source in vitro, which is dependent on the glyoxylate shunt to 
prevent loss of carbon in the form of CO2. To enter into carbon metabolism, acetate is 
converted to acetyl-CoA by the enzyme acetyl-CoA synthetase (ACS), encoded by 
Rv3667 (Li et al., 2011). ACS is known to be inhibited by acetylation or 
propionylation (Noy et al., 2014). An alternative acetate incorporation pathway exists 
in E. coli and C. glutamicum that involves the enzymes acetate kinase and 
phosphotransacetylase and the intermediate metabolite acetyl-phosphate. Mtb encodes 
a homolog for acetate kinase (ackA, rv0409) and phosphotransacetylase (pta, rv0408). 
Acetate induces upregulation of icl1, which encodes isocitrate lyase, the first enzyme 
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in the glyoxylate shunt. icl1 is repressed during growth on glucose through the activity 
of transcriptional repressor RamB (Micklinghoff et al., 2009).  
Propionate is a three-carbon carboxylate ion. Propionate is metabolized into 
propionyl-CoA by ACS, which has been shown to function as a propionyl-CoA 
synthase (Li et al., 2011). Propionyl-CoA derived from lipids such as cholesterol or 
long-chain fatty acids is thought to play a critical role in Mtb virulence. Propionyl-
CoA is required for the synthesis of cell wall lipids such as phthiocerol 
dimycocerosate (PDIM), which have been implicated in pathogenicity (Day et al., 
2014). However, propionate and its derivatives are toxic to the cell. Three mechanisms 
of propionate detoxification have been proposed in Mtb: the methylcitrate pathway, 
the methylmalonyl pathway, and the incorporation of propionate into cell wall 
lipids(Lee et al., 2013). Indeed, increasing incorporation of propionate into TAG and 
PDIM through deletion of whiB3 enhanced resistance to propionate (Singh et al., 
2009).   
How is propionate toxic to the cell? In Aspergillus nidulans, propionyl-CoA was 
shown to inhibit the CoA-dependent enzyme pyruvate dehydrogenase (Brock and 
Buckel, 2004). A similar mechanism has been proposed for Mtb, as addition of acetate 
to conditions with propionate (in the presence of glycerol) relieved propionate toxicity 
for a strain lacking isocitrate lyase activity (Lee et al., 2013). Also, 2-methylcitrate (a 
metabolite downstream of propionyl-CoA) in Mtb has been shown to have an 
inhibitory effect on fructose bisphosphatase (Eoh and Rhee, 2014). Accumulation of 
methylcitrate cycle intermediates has further been implicated in the disruption of 
membrane potential, intrabacterial pH, and NAD+/NADH ratio in Mtb (Eoh and Rhee, 
2014). It is possible that these mechanisms or others account for toxicity of propionate 
or propionate-derived metabolites within the cell.   
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Considering this propionate toxicity, it not surprising that Mtb has evolved ways of 
regulating propionate metabolism. Acetyltransferase (KAT) can acetylate ACS, which 
inactivates the enzyme, inhibiting incorporation of propionate into propionyl-CoA. 
Deletion of KAT enhanced susceptibility to propionate, presumably by allowing 
greater flux of propionate into the methylcitrate cycle (Nambi et al., 2013). In addition 
to regulation of ACS, Mtb has other mechanisms by which it responds to propionate. 
PrpR (encoded by rv1129c) is a transcription factor that is required for expression of 
prpC and prpD, genes encoding methylcitrate synthase and methylcitrate dehydratase, 
respectively (Griffin et al., 2011; Masiewicz et al., 2012). In both cholesterol and 
propionate, prpC and prpD are upregulated in a PrpR-dependent manner, and Mtb 
lacking rv1129c has growth defects in propionate or cholesterol alone. PrpR binds the 
promoter region of prpC, prpD, and icl1, which activates the transcription of these 
genes. PrpR also binds the promoter region of the icl1 transcriptional regulator ramB 
and weakly interacts with the promoter region of dnaA, which inhibits expression of 
these genes (Masiewicz et al., 2014). DnaA plays a role in replication initiation, so 
activation of PrpR through exposure to propionate could be a mechanism by which 
Mtb slows its process of cell division (Masiewicz et al., 2014). Interestingly, 
expression of prpC and prpD is not upregulated in acetate-containing media, so it 
appears that PrpR activity is activated by propionyl-CoA-generating carbon sources 
(propionate and cholesterol) specifically.  
Fatty acids 
Mtb encodes approximately 250 genes involved in lipid metabolism, suggesting that 
lipids (including fatty acids) are a critical component of Mtb’s diet (Cole et al., 1998). 
Fatty acids are carboxylic acids with hydrocarbon chains. Mtb can use many different 
fatty acids as carbon sources, such as butyrate, valerate, caproate, oleic acid, and 
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stearate (Lee et al., 2013). Fatty acids are catabolized via β-oxidation into one or 
several molecules of acetyl-CoA and one molecule of propionyl-CoA (for odd-chain 
fatty acids). Fatty acids may diffuse freely through membranes or they may have 
specific transporters; the mechanisms of uptake for most fatty acids are unknown.  
A fatty acid present in standard Mtb culture media is oleic acid. Oleic acid is an 18-
carbon long monounsaturated fatty acid that enhances growth of WT Mtb. WT Mtb 
growing on media with low quantities of oleic acid (0.006%) forms colonies on plates 
more quickly and also increases in density more quickly in liquid media. As with other 
fatty acids, the mechanism of oleic acid uptake is unknown but may involve a 
transporter or permeation through mycobacterial membranes. 
Cholesterol 
Cholesterol is a complex lipid that is a major component of animal cell membranes 
and is likely catabolized by Mtb during infection. Mtb encodes multiple genes 
involved in cholesterol transport and catabolism, many included in the “Cho” region 
of the genome that comprises 83 genes, spanning from Rv3492c to Rv3574 (Van der 
Geize et al., 2007; Nesbitt et al., 2010). Additional genes also participate in cholesterol 
utilization, as a transposon mutagenesis screen identified 96 genes predicted to be 
required for growth on cholesterol, some outside of the Cho region (Griffin et al., 
2011). Mtb can grow on cholesterol as a carbon source in vitro, which is metabolized 
via a complex series of steps into a mixture of propionyl-CoA, acetyl-CoA, and 
pyruvate (Griffin et al., 2012; Wipperman et al., 2014). Metabolism of cholesterol is 
dependent on the methyl-citrate pathway in the absence of a functional methylmalonyl 
pathway, likely due to the need for propionate detoxification (Griffin et al., 2012). 
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Amino Acids 
Amino acid synthesis and degradation pathways are closely connected to carbon 
metabolic pathways in Mtb. For example, alanine, leucine and valine can contribute to 
pyruvate synthesis; aspartate, asparagine, methionine, lysine, isoleucine, and threonine 
are connected to oxaloacetate synthesis; and glutamate, glutamine, arginine, and 
proline contribute to α-ketoglutarate synthesis (Kim, 2008). Several transporters have 
been identified as playing a role with uptake of amino acids, which are also important 
for nitrogen metabolism (Gouzy et al., 2014). For example, AnsP1 is involved in 
uptake of aspartate, which in the presence of another carbon source (such as glycerol) 
can incorporate into TCA cycle metabolites (Gouzy et al., 2013). Asparagine has also 
been demonstrated to be used as a carbon source by Mtb (Lyon et al., 1969). 
Glutamate can be converted to α-ketoglutarate through the action of glutamate 
dehydrogenase. α-ketoglutarate is at the branch point of carbon and nitrogen 
metabolism, and its fate is controlled by the regulator GarA. GarA inhibits both 
glutamate dehydrogenase and α-ketoglutarate dehydrogenase only in its non-
phosphorylated form. Unphosphorylated GarA also activates glutamate synthase (also 
known as glutamine oxoglutarate amidotransferase or GOGAT). This promotes use of 
α-ketoglutarate for glutamate synthesis. While phosphorylated, GarA does not inhibit 
these enzymes, and α-ketoglutarate contributes to the TCA cycle (Ventura et al., 2013).  
Multiple carbon sources 
Mtb differs from bacteria such as E. coli in that it lacks homologs for carbon catabolite 
repression pathways and has the ability to utilize two carbon sources feeding into 
opposing pathways to enhance its growth (de Carvalho et al., 2010a; Görke and Stülke, 
2008). This simultaneous utilization of carbon sources is referred to as co-catabolism. 
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This seemingly contradicts the concept of metabolic regulatory mechanisms being in 
place to prevent waste of energy through futile cycling. An explanation for how Mtb 
prevents futile cycling has been suggested with metabolomics labeling experiments 
revealing a compartmentalization of Mtb metabolic pathways (de Carvalho et al., 
2010a). For example, in the case of two carbon sources glucose and acetate, glucose 
primarily contributes to glycolytic intermediates, whereas acetate feeds into the TCA 
cycle. Whether this compartmentalization involves segregation of metabolic enzymes 
into separate intracellular compartments or into enzyme complexes remains to be 
determined. Also, whether Mtb requires the ability to co-catabolize carbon within the 
host environment remains to be determined.  
No or low carbon 
There may be times in which Mtb encounters a lack of carbon sources or inability to 
generate amino acids it needs. The stringent response is a metabolic slow-down that 
requires the enzyme RelA to generate the alarmone (p)ppGpp (hyperphosphorylated 
guanosine nucleotides) which inhibits RNA polymerase function (Klinkenberg et al., 
2010). The activity of RelA is regulated by the concentration of amino acids present in 
the cell. RelA deletion impairs Mtb virulence in mouse and guinea pig models, 
suggesting a role for the stringent response in vivo (Klinkenberg et al., 2010; Primm et 
al., 2000). However, it is unclear whether complete deprivation of carbon sources in 
vivo would be required to activate this response, or if lack of other nutrients could also 
trigger this response.  
Carbon dioxide 
Carbon dioxide (CO2) can be converted by carbonic anhydrases (of which Mtb 
encodes three) to bicarbonate (HCO3), which can be used as a substrate for 
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anapleurotic reactions from glycolysis to the TCA cycle, and for condensation with 
propionyl-CoA in the methylmalonyl pathway (Beste et al., 2011). Therefore, CO2 is 
not sufficient on its own to support growth as a carbon source, but can supplement 
growth in the presence of other carbon sources. Evidence for this includes 
incorporation of labeled sodium bicarbonate into metabolites of the TCA cycle (Beste 
et al., 2011, 2013).  
1.3.2.3 Genetic knockout studies identify essential pathways 
Genetic studies involving mouse infections with Mtb knockout or knockdown strains 
have bolstered our understanding of the importance of carbon metabolic pathways in 
Mtb in vivo. The importance of fatty acid metabolic pathways during infection was 
first established in a landmark paper by McKinney et. al in 2000, which showed that 
deletion of one of the genes encoding the glyoxylate shunt enzyme isocitrate lyase 
impaired Mtb persistence in the mouse model (McKinney et al., 2000). Subsequent 
studies demonstrated that depletion of both isocitrate lyase genes rendered Mtb unable 
to establish or maintain infection in mice (Blumenthal et al., 2010; Munoz-Elias and 
McKinney, 2005). Interestingly, activated macrophages have been shown to produce 
the ICL inhibitor itaconic acid as an antibacterial response, supporting an important 
role for the glyoxylate shunt during infection (Michelucci et al., 2013). However, ICL 
also has an alternative function as a methylisocitrate lyase, which is involved in the 
methylcitrate cycle, a propionate detoxification pathway. Mutations in the 
methylcitrate cycle genes prpDC (encoding for methylcitrate synthase and 
methylcitrate dehydrogenase) did not result in a mouse phenotype but did impair 
growth of Mtb in murine macrophages ex vivo (Muñoz-Elías et al., 2006).  
The importance of gluconeogenesis during mouse infection was demonstrated by the 
deletion or depletion of phosphoenolpyruvate carboxykinase (PEPCK), the first 
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committed step of gluconeogenesis (Marrero et al., 2010). Mtb lacking pckA, the gene 
encoding PEPCK, had difficulty establishing infection in mice and was impaired for 
growth with acetate or valerate as a single carbon source. Furthermore, depletion of 
pckA after establishment of infection resulted in a reduction of bacterial burden. 
Interestingly, the pckA knockout did not die during any in vitro condition tested, 
including low pH, oxidative stress, nitric oxide, or starvation. The mechanism of death 
in vivo therefore remains to be elucidated.   
Glycolysis may also contribute to virulence during infection. Import of trehalose, a 
carbon source feeding into glycolysis, was required for establishment of infection in 
mice (Kalscheuer et al., 2010). Glucose phosphorylation, the first step in glycolysis 
catalyzed by the proteins encoded by ppgK and rv0650, was essential for persistence 
of infection (Marrero et al., 2013). Also, triose phosphate isomerase (encoded by tpi), 
an enzyme downstream of glucose phosphorylation in glycolysis, was required for 
Mtb growth and survival in glycerol, and establishment of infection in mice (Trujillo 
et al., 2014). However, tpi also participates in gluconeogenesis. Trehalose can also 
contribute to glycolipid formation. Also, knockout of the only phosphofructokinase 
gene exhibiting enzymatic activity (pfkA) did not impair Mtb’s ability to establish or 
maintain infection in vivo (Phong et al., 2013). Therefore, there is evidence supporting 
a role for glycolysis during infection, although it is not as substantial as that for 
gluconeogenesis.  
Another gene involved in carbon metabolic pathways that was essential in the mouse 
model is lpdC, which encodes lipoamide dehydrogenase (Lpd) (Venugopal et al., 
2011). Lpd participates in four enzyme complexes: pyruvate dehydrogenase (PDH), 
branched chain ketoacid dehydrogenase (BCKADH), peroxynitrite 
reductase/peroxidase (PNR/P), and α-ketoglutarate dehydrogenase (KGD). This is in 
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contrast to Dlat, which participates in PDH, PNR/P, and KGD complexes but not 
BCKADH. Dlat-deficient bacteria were less severely attenuated in vivo compared to 
Lpd-deficient bacteria (Wagner et al., 2011). BCKADH likely prevents toxic buildup 
of branched chain ketoacids, pyruvate, or branched chain amino acids, but it could 
also feed into central metabolism by providing carbon from amino acid breakdown. 
These data show that while Mtb may be able to cope with loss of two steps in central 
carbon metabolic pathways (PDH and KGD) along with PNR/P activity, additional 
loss of BCKADH activity is difficult for Mtb to overcome.  
Genetic studies are also informative about roles of particular carbon sources during 
infection. For example, it is unlikely that Mtb uses glycerol as a carbon source during 
infection, as an Mtb inhibitor that was dependent on glycerol for its inhibitory effect 
was ineffective at inhibiting growth of Mtb in the mouse model. This glycerol-induced 
toxicity was thought to be induced by blockage of the methylglyoxyl bypass leading to 
the accumulation of methylglyoxal (Pethe et al., 2010). Furthermore, a mutant 
deficient in glpK, which encodes glycerol kinase, the first step of glycerol catabolism, 
was not attenuated during infection (Pethe et al., 2010).  
Conversely, genetic studies support a critical role for cholesterol metabolism during 
persistent Mtb infection of mice and humans. A transposon mutant screen for genes 
essential for growth on cholesterol identified many genes also shown to be essential 
within the mouse model (Griffin et al., 2011). A cholesterol ABC-type transporter 
encoded by the mce4 gene cluster is required for optimal growth in cholesterol, and 
deletion of this transporter impaired the ability of Mtb to maintain infection in the 
mouse model (Pandey and Sassetti, 2008). Mutations in the igr locus, involved in 
cholesterol catabolism, prevent Mtb growth in cholesterol and render Mtb less able to 
establish infection in the mouse model (Chang et al., 2009). However, deletion of 
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cholesterol transporter mce4 in addition to igr deletion prevented cholesterol-mediated 
growth inhibition and enhanced Mtb virulence in the mouse compared to igr deletion 
alone. This suggests that blockage of cholesterol catabolism can generate toxic 
byproducts, and that cholesterol is internalized and metabolized throughout infection.   
Together these studies outline a critical role for lipid metabolic pathways, but do not 
eliminate a role for glycolysis during infection. Furthermore, they exemplify the use of 
genetic studies to better understand the role for carbon metabolic pathways during 
infection.  
1.4 Thesis mission statement and aims 
The goal of the work in this thesis was to evaluate potential drug targets in Mtb 
metabolism and to better understand their roles in Mtb pathogenesis. We focused on 
two key enzymes, fructose bisphosphate aldolase and malate synthase, both of interest 
as drug targets but lacking genetic studies. Here we describe the generation and 
characterization of Mtb mutants lacking these enzymes, investigate their roles in Mtb 
growth, survival, and pathogenesis, and contribute to our understanding of the 
importance and function of carbon metabolic pathways in Mtb.  
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CHAPTER 2 
THE ROLE OF FRUCTOSE 1,6-BISPHOSPHATE ALDOLASE IN 
PATHOGENICITY OF MYCOBACTERIUM TUBERCULOSIS* 
 
2.1  Introduction  
Identification of enzymes essential for pathogenicity and persistence of 
Mycobacterium tuberculosis (Mtb) is critical for guiding the development of novel 
anti-tuberculosis drugs. Enzymes that are mechanistically or structurally different than 
their human counterparts are attractive as drug targets. We thought the carbon 
metabolic enzyme fructose 1,6-bisphosphate aldolase (FBA) could match these criteria. 
However, the importance of FBA during infection of an animal model had not been 
demonstrated. To investigate this, we generated an FBA conditional knockdown 
mutant to silence FBA during a mouse model of infection. We also characterized 
growth of this knockdown strain upon FBA silencing, enabling us to identify the 
conditions that we used to generate a strain lacking FBA. These knockdown and 
knockout strains allowed us to assess FBA as a drug target as well as to contribute to 
understanding of FBA’s essentiality within the host and in specific carbon source 
conditions.  
 
 
 
*Puckett, S., Trujillo, C., Eoh, H., Marrero, J., Spencer, J., Jackson, M., Schnappinger, D., Rhee, K., 
Ehrt, S. (2014). Inactivation of fructose-1,6-bisphosphate aldolase prevents optimal co-catabolism of 
glycolytic and gluconeogenic carbon substrates in Mycobacterium tuberculosis. PloS Pathog 10(5): 
e1004144. 
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2.2 Background 
Fructose 1,6-bisphosphate aldolase (FBA) is a metabolic enzyme central to glycolysis 
and gluconeogenesis. It catalyzes the reversible conversion of fructose-1,6-
bisphosphate to dihydroxyacetone-phosphate (DHAP) and glyceraldehyde 3-
phosphate (G3P). This step is critical for enabling the carbon from fructose 1,6-
bisphosphate to participate in an ATP-generating downstream reaction catalyzed by 
glyceraldehyde-3-phosphate dehydrogenase. Furthermore, this reaction prevents a 
potentially toxic buildup of sugar phosphates. In the reverse direction, FBA is critical 
for the generation of bacterial cell wall precursor fructose 6-phosphate, as well as for 
the generation of glucose 6-phosphate, a precursor for nucleic acid synthesis.  
FBAs are found in all domains of life on earth, and FBA disruptions or inhibitions 
have been shown to be problematic for a variety of organisms. In E. coli, nickel 
toxicity is caused by FBA inhibition (Macomber et al., 2011). Depletion of FBA in 
Candida albicans is growth inhibitory (Rodaki et al., 2006). Mutations in human 
ALDOA are associated with hemolytic anemia (Kishi et al., 1987) and ALDOA is a 
potential marker for human squamous cell carcinoma (Du et al., 2014). This presence 
of FBA in humans as well as pathogens highlights the importance of designing 
pathogen-specific FBA inhibitors. Fortunately, this may be possible due to differences 
in the reaction mechanism.  
FBAs are grouped into two classes based on their reaction mechanism. Class I FBAs 
form a Schiff base intermediate, whereas Class II FBAs lack this intermediate and 
instead rely on a divalent metal cation (such as Zn2+) to stabilize a hydroxyenolate 
intermediate (Pegan et al., 2013). Plants and animals, including humans, express class 
I FBAs, whereas prokaryotes can express either or both Class I and Class II FBAs. It 
was earlier hypothesized that Class II FBAs are evolutionarily primitive because they 
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do not exist in humans and higher mammals, but the subsequent discovery of Class I 
FBAs in prokaryotes suggested otherwise (Marsh and Lebherz, 1992). It is possible 
that organisms lacking one of the classes have eliminated the other due to functional 
redundancy. However, in E. coli, there are both classes but only Class II is essential 
(Pegan et al., 2009).  
In Mtb, there is only one annotated FBA, a Class II enzyme encoded by the gene fba 
(rv0363c) (Figure 2.1). Early enzymatic assays detected both Class I and Class II 
activity in Mtb lysates, which can be differentiated by the use of a metal chelator to 
inactivate the metal-dependent Class II activity (Bai et al., 1974). Class I activity was 
detected primarily in high oxygen conditions. However, in a recent study Class I 
activity was not detectable in any condition tested, which included cells in log or 
stationary phase of growth, cells in low or high oxygen conditions, and cells in media 
containing acetate alone vs. ADNaCl, a growth supplement containing glucose (de la 
Paz Santangelo et al., 2011). Interestingly, Class II FBA activity was present but did 
not vary widely between any of these conditions, although FBA protein was found to 
be upregulated in culture filtrates in hypoxic conditions (Rosenkrands et al., 2002). 
Furthermore, the Mtb Class II enzyme is expressed during guinea pig and IFNγ 
knockout mice infection, suggesting it has a physiologically relevant role in 
pathogenesis (de la Paz Santangelo et al., 2011).  
Is fba essential in Mtb? There is conflicting data between recent transposon 
mutagenesis studies, where fba was predicted essential (unable to tolerate insertions) 
for Mtb growth in minimal medium but not in rich medium (Griffin et al., 2011; 
Zhang et al., 2012). However, attempts to make the direct knockout have failed (Pegan 
et al., 2009). As shown using a conditional fba knockdown strain, growth of a non-
pathogenic H37Ra strain in single carbon sources depends on fba  
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Figure 2.1. Schematic of glycolysis, gluconeogenesis, and the tricarboxylic acid 
(TCA) cycle in Mtb. Enzymes and their corresponding genes are color coded to 
reflect their dedicated pathways: glycolysis and pentose phosphate pathway (blue), 
gluconeogenesis (red), glycolysis and gluconeogenesis (purple), TCA cycle (green), 
and glyoxylate shunt (orange). 
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(de la Paz Santangelo et al., 2011). Studies like these have led to the conclusion in the 
literature that Mtb FBA is essential (Labbé et al., 2012). However, essentiality in an 
animal model has not been demonstrated.  
Outside of its role in carbon metabolism, FBA has been shown to be secreted and may 
play a role in host interaction. In Neisseria meningitidis, FBA was shown to localize to 
the cytoplasm and the outer membrane and plays a role in host cell adhesion (Tunio et 
al., 2010). Toxoplasma aldolase may play a role in parasite motility and invasion, 
although its primary function is metabolic (Shen and Sibley, 2014). A “moon-lighting” 
function of FBA may also exist in Mtb, as FBA can bind to human plasminogen, but 
the importance of this function in pathogenesis is yet to be elucidated (de la Paz 
Santangelo et al., 2011).  
FBAs, including the Mtb FBA, have been the focus of structural, enzymatic and drug 
developmental studies. The structure of the Mtb FBA has been solved, and FBA (344 
amino acids long, 36.5 kDa as a monomer) is thought to form a tetrameric complex or 
“dimer of dimers” with a known tetramerization region that extends away from the 
rest of the protein. The importance of specific active site residues was examined and 
recombinant FBA with a mutation in the active site (E169A) had substantially reduced 
FBA activity (Pegan et al., 2013). The availability of in-depth structural knowledge 
has contributed to the development of Class II FBA-specific inhibitors, including 
substrate analogs, metal chelators and a non-competitive inhibitor (Capodagli et al., 
2014; Daher et al., 2010; Fonvielle et al., 2008; Labbé et al., 2012).  The FBA protein 
is 100% conserved across all sequenced strains of Mtb, including drug-resistant strains, 
meaning that an inhibitor effective against one Mtb FBA structure should be effective 
against others (Capodagli et al., 2014). However, only one inhibitor yet has shown to 
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inhibit live Mtb in vitro at a concentration of 0.6-1.2 mM (Capodagli et al., 2014), and 
none have been used in an animal model.  
We aimed to assess FBA as a drug target and to understand its in vitro essentiality by 
generation and use of a conditional knockdown fba Mtb strain. This genetic tool 
allowed us to demonstrate a role for FBA in pathogenesis of Mtb in the mouse model 
but also revealed that fba essentiality is carbon source-dependent. Subsequent 
generation and characterization of an fba knockout strain highlighted a role for FBA in 
Mtb survival in single carbon sources, and also for co-catabolism of carbon substrates. 
2.3 Results 
2.3.1 FBA is required for growth in glycolytic and gluconeogenic carbon 
sources and for growth and persistence in mice 
To investigate the role of FBA in vitro and in vivo we generated an Mtb strain in 
which expression of FBA is regulated by the recently described DUC switch (Kim et 
al., 2013), so that anhydrotetracycline (atc) or doxycycline (doxy) trigger 
transcriptional repression of the fba gene and simultaneous degradation of the FBA 
protein, as recently described. We first introduced a second copy of fba with a strong 
promoter (Psmyc-fba) via an integrative plasmid into the Mtb chromosome and then 
deleted the native copy (Ehrt et al., 2005). After confirming fba deletion by Southern 
blot (Figure 2.2A-B), we generated FBA-DUC by replacing Psmyc-fba with a DAS+4-
tagged fba gene, whose transcription was controlled by a TetR-regulated promoter. 
The DAS+4-tag allowed for proteolytic inactivation of FBA. Immunoblot analysis 
confirmed FBA depletion upon addition of atc (Figure 2.3). Similar to previous 
findings with an H37Ra FBA-TetON mutant (de la Paz Santangelo et al., 2011), 
growth of H37Rv FBA-DUC with single carbon sources was inhibited when FBA was 
depleted by the addition of atc (Figure 2.4A-C). Unexpectedly, however, growth of  
	  	  53 
               
               
Figure 2.2. Confirmation of fba deletion in fba mutant strains. (A) Genomic 
organization and Southern blot design with (1) native fba locus before and after 
replacement with a hygromycin resistance cassette and (2) attL5 phage integration site 
after integration of the plasmid containing fba transcribed by a strong promoter (Psmyc-
fba). A 1 kb probe spanning Rv0364 and fba detects SacI-digested DNA fragments 
either containing the fba locus or fba elsewhere in the genome (see supplemental for 
sequence). (B). Southern blot showing the expected band patterns for wild type (WT) 
and fba mutants. WT, with a 4024 kb band indicative of an intact native fba locus, was 
transformed with Psmyc-fba, resulting in a 8809 bp band indicative of Psmyc-fba 
integration at the attL5 site. Then we deleted native fba in this merodiploid strain by 
replacing it with a hygromycin resistance cassette. This mutant strain expresses fba at 
the attL5 site but not in the native locus and we observed the new expected band 
pattern of 2787 bps. The knockout was generated by replacement transformation, in 
which we selected for loss of Psmyc-fba (streptomycin sensitivity) and gain of a new 
plasmid (kanamycin resistance) not containing fba. Southern blot confirmed loss of 
the band indicative of fba at the attL5 site revealing only one band of 2787 bps. This 
knockout strain is referred to as Δfba.  
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Figure 2.3. FBA expression in WT and mutants. FBA (36.5 kDa) immunoblot in 
protein extracts from the indicated strains grown in 7H9 media with glucose and 
glycerol as carbon sources. In FBA-DUC the DAS+4 tag increases FBA’s molecular 
weight by 1.6 kDa. Anhydrotetracycline (atc) was added at 500 ng/ml. FBA antiserum 
was applied for one hour at a 1:3500 dilution. PrcB (30.3 kDa) served as loading 
control.  
  
WT Δfba 
Δfba-
comp FBA-DUC 
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Figure 2.4. FBA depletion inhibits growth of Mtb in single carbon sources, but 
not in the presence of both a glycolytic and a gluconeogenic carbon source. 
Growth of WT (black squares) and FBA-DUC in the absence (grey circles) and 
presence (open circles) of 500 ng/ml atc in carbon defined media containing (A) 0.4% 
glucose (B) 0.4% glycerol (C) 0.1% butyrate (D) 0.2% glucose and 0.2% glycerol (E) 
0.2% glucose and 0.1% butyrate or (F) no carbon.. Bacteria were cultured in 25 cm2 
flasks. Data are representative of at least two independent experiments.  
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FBA-DUC was unaffected by atc in media containing glucose and a second carbon 
source, such as butyrate, or glycerol (Figure 2.4D-E).  
To assess if FBA is required in vivo, we infected mice with WT and FBA-DUC and 
monitored growth and survival in lungs and spleens (Figure 2.5). Mice infected with 
FBA-DUC were fed doxy-containing chow starting at the day of infection, on day 10, 
and on day 35 post-infection to determine whether FBA is required for growth and 
persistence of Mtb. FBA-DUC failed to replicate in lungs of mice fed with doxy 
starting on the day of infection and was undetectable by CFU determinations at day 10 
post-infection (Figure 2.5A). No pathological signs of infection were observed in 
lungs of these mice (not shown) and no CFU were detectable in their spleens. When 
doxy administration was started later, CFU declined rapidly in lungs and spleens of 
both acutely and chronically infected mice. Decreases in CFU were accompanied by 
decreases in lung pathology (Figure 2.5B). In mice that did not receive doxy, FBA-
DUC replicated and persisted similar to WT. Together these data establish that Mtb 
requires FBA activity for growth during acute and persistence during chronic mouse 
infections. 
2.3.2 FBA essentiality is carbon source-dependent 
Growth of FBA-DUC with atc in dual carbon source media (Figure 2.4) suggested that 
FBA may not be essential in all conditions and that its essentiality may be carbon 
source-dependent. Therefore, we next attempted to delete fba by replacing the 
integrative, plasmid containing Psmyc-fba with a plasmid that did not contain fba. Δfba 
candidates grew readily on agar plates containing a carbon source combination - 
glucose and glycerol - that permitted growth of FBA-DUC with atc (Figure 2.6). No 
Δfba candidates were obtained on standard Mtb agar plates with glycerol and 
Middlebrook OADC, a supplement containing oleic acid and glucose as carbon  
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Figure 2.5. FBA is required for replication and persistence of Mtb in mice. (A) 
Growth and survival of WT (squares) and FBA-DUC (circles) in mouse lungs (left 
panel) and spleens (right panel). Mice infected with FBA-DUC received doxy-
containing food from the day of infection (day 0), day 10, day 35 or not at all as 
indicated. CFU were not detected in spleens from mice infected with FBA-DUC and 
treated with doxy starting day 0. The limit of detection was 4 CFU in lungs and 
spleens. Data are means ± SD of four mice, except for three data points which derive 
from 3 and 2 mice due to the appearance of atc/doxy doxy resistant revertants in the 
lungs (day 57 FBA-DUC + doxy day 10, day 85 FBA-DUC + doxy day 10 and day 
112 FBA-DUC + doxy day 35). (B) Gross pathology and H&E staining of lung 
sections from mice infected with FBA-DUC. Lungs were isolated at day 35 (upper 
panel) and day 112 (middle and lower panel) from mice not treated and administered 
doxy starting day 35 post infection. A second short course infection experiment 
reproduced the phenotype of FBA-DUC in mice not treated or treated with doxy 
starting on the day of infection. 
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Figure 2.6. FBA essentiality is carbon source dependent. (A) Growth of 
replacement transformants of Mtb Psmyc-fba-fba::hyg with a plasmid not containing fba 
and thus resulting in Δfba on agar plates containing the indicated carbon sources. (B) 
Growth of Δfba in 7H9 base liquid media with identical carbon sources as in the above 
plate conditions.  
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sources. However, doubling the glucose concentration resulted in growth of colonies 
albeit with slower growth rate than in the absence of oleic acid (Figure 2.6A).  
Southern blot and immunoblot confirmed that the Δfba candidates were true knockout 
strains (Figure 2.2, 2.3). As observed on agar plates, growth of Δfba in liquid culture 
was carbon source-dependent, although Δfba replicated in oleic acid-containing 
medium following a twenty-day lag phase (Figure 2.6B). This delayed growth was not 
from complete fba suppressor mutants because these bacteria were not capable of 
growth with a single carbon source (Figure 2.7). Whole genome sequencing of an 
OADC-resistant Δfba strain revealed two mutations compared to parent Δfba strain: 
an amino acid substitution in probable heat shock protein transcriptional repressor 
hrcA (A123V) and a stop mutation in a probable membrane anchor for succinate 
dehydrogenase rv0249c (W31*). The latter caught our interest due to its role in the 
TCA cycle. Mtb encodes at least two putative succinate dehydrogenase operons, 
sdhABCD (rv3316-rv3319) and rv0249c-rv0247c. Therefore, truncation of rv0249c 
could lead to slow down, but potentially not complete blockage, of the TCA cycle. 
Alternatively, succinate may also buildup to a greater extent in the event of reduced 
succinate dehydrogenase activity. Future work involving metabolomics analysis of 
labeled carbon substrates could address these possibilities and examine how these 
changes allow for growth.  
These experiments demonstrated that essentiality of FBA is conditional and suggested 
that Mtb lacking FBA (Δfba) has specific carbon source requirements. Similar to the 
effects of conditional FBA-depletion, complete inactivation of FBA by deletion of fba 
caused a failure to replicate with a single carbon source but did not significantly affect 
growth with two carbon sources that enter central carbon metabolism above and below 
the FBA catalyzed step (Figure 2.8A). Growth of the complemented strain (Δfba-  
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Figure 2.7. OADC-resistant fba KO strain does not grow in single carbon 
sources.  Growth of the WT, Δfba, and Δfba OADC-resistant strains were grown in 
(A) 7H9 base media with 10% ADNaCl (made with fatty acid-free BSA) plus 0.2% 
glycerol, (B) 7H9 base media with 10% OADC (for a final of 0.006% oleic acid) and 
0.5% glycerol, (C) carbon-defined minimal media with 0.4% glucose, or (D) carbon-
defined minimal media with 0.1% butyrate.  
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Figure 2.8. FBA is required for growth and survival in single carbon sources. (A) 
Growth measured by absorbance of WT (black squares), Δfba (open triangles) and 
Δfba-comp (grey triangles) in carbon-defined media containing glucose, glycerol and 
butyrate at the indicated concentrations. Bacteria were cultured in 25 cm2 flasks. (B) 
Survival measured by culturing for CFU on growth-permissive agar plates of the 
indicated Mtb strains in media with single carbon sources and no carbon addition at 
different time points post-inoculation. Stippled lines indicate that next data point was 
below the limit of detection. 
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comp) was similar to that of WT in all conditions tested, demonstrating that the 
observed growth phenotypes were caused by the lack of FBA. CFU analysis of Δfba in 
single carbon sources revealed that Δfba died rapidly, with a 5 log decrease in CFU in 
7 days and no detectable CFU by day 14 in media containing glycerol, butyrate, or 
acetate as sole carbon sources (Figure 2.8B, data not shown for acetate). Death in 
glucose-containing medium was slower, but also substantial. In contrast, Δfba 
survived with only a 10-fold decrease in CFU in base media without added carbon. 
Thus, the presence of a single carbon source resulted in killing of Δfba and the 
kinetics of death were dependent on the specific carbon source suggesting that the 
mechanism leading to death of Δfba in glucose may be different from that induced by 
glycerol or butyrate feeding below the FBA catalyzed step.  
Δfba failed to replicate in resting bone marrow derived mouse macrophages (BMDM) 
in contrast to WT and Δfba-comp (Figure 2.9A). Activation of macrophages with 
IFNg reduced replication of WT and Δfba-comp and did not affect survival of Δfba. In 
mice, Δfba did not establish an infection and was cleared from mouse lungs by day 10 
post infection (Figure 2.9B). Thus, the metabolic environment in phagosomes of 
macrophages ex vivo and in mouse lungs did not support growth of Mtb in the absence 
of FBA and resulted in killing of Δfba in mice. The lack of death of Δfba in isolated 
macrophages suggests that the intracellular environment in macrophages ex vivo does 
not exactly mimic that faced by Mtb in macrophages inside the lung.  
2.3.3 Metabolic consequences of fba deletion 
To better understand the impact of loss of FBA on Mtb metabolism we used liquid 
chromatography/mass spectrometry to measure metabolite levels in WT, Δfba, and 
Δfba-comp cultured on filters on top of agar plates containing 0.2% glucose, 0.2%  
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Figure 2.9. FBA is required for replication in macrophages and growth and 
survival in mouse lungs. (A) Bacterial loads in resting and IFNg activated mouse 
bone marrow derived macrophages (BMDM) infected with carbon-starved WT, Δfba 
and Δfba-comp. Data are means +/- SD of triplicate wells. *P≤0.05; **P≤0.005 by 
Student’s t-test (B) Growth and survival of WT and Δfba in mouse lungs. Data are 
means +/- SD from four mice. Limit of detection was 4 CFU and Δfba was not 
detectable on days 10 and 21. 
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Figure 2.10. Metabolic consequences of fba deletion. Intrabacterial pool sizes of 
selected metabolites (nmol/mg protein) in the indicated Mtb strains after 24 hours 
culture on media containing either glucose (Gluc), glycerol (Gly) or a combination of 
both. nd = not detected. All values are means of measurements from two independent 
experiments, each performed with triplicate cultures ± SEM. *P≤0.05; **P≤0.005; 
***P≤0.0005 by Student’s t-test. ALA, alanine; α-KG, α-ketoglutarate; ASP, 
aspartate; CIT/ISOCIT, citrate/isocitrate; DHAP, dihydroxyacetone phosphate; E4P, 
erythrose 4-phosphate; FBA, fructose 1,6-bisphosphate aldolase; F6P, fructose 6-
phosphate; FBP, fructose 1,6-bisphosphate; FUM, fumarate; G3P, glyceraldehyde 3-
phosphate; G6P, glucose 6-phosphate; MAL, malate; OAA, oxaloacetate; PEP, 
phosphoenolpyruvate; PYR, pyruvate; R5P, ribose 5-phosphate; RU5P, ribulose 5-
phosphate, SH7P, sedoheptulose 7-phosphate; SUC, succinate; X5P, xylulose 5-
phosphate. 
	  	  65 
glycerol, or a combination of 0.2% glucose and 0.2% glycerol (Figure 2.10). 
Following exposure to glucose alone, Δfba accumulated high levels of hexose- 
phosphate (P) and depleted its triose-P and phosphoenolpyruvate (PEP) pools. These 
metabolic changes are consistent with a defect in glucose metabolism due to the 
absence of FBA activity. Pentose-P and sedoheptulose-P pools were also significantly 
increased in Δfba suggesting either increased flux through the pentose phosphate (PP) 
pathway or decreased metabolism of PP pathway intermediates. In contrast, exposure 
to glycerol as sole carbon source resulted in depletion of hexose-P and sedoheptulose-
P pools while triose-P levels were increased. The presence of both glucose and 
glycerol reversed most metabolic changes in Δfba except for the triose-P pool, which 
remained elevated, but not to the same extent as with glycerol as sole carbon source. 
These experiments demonstrate that metabolism of single carbon sources by Δfba 
significantly altered intracellular metabolite concentrations, which was accompanied 
by cell death (Figure 2.8B). The buildup of PP pathway metabolites was consistent 
with increased flux into the PP pathway during culture on glucose; however, the PP 
pathway could not act as an efficient bypass to overcome loss of FBA. 
2.3.4 Only a specific balance of carbon sources can compensate for lack of FBA 
Growth of Δfba required the presence of two carbon sources entering metabolism 
above and below the FBA catalyzed reaction and on agar plates was dependent on the 
amount of glucose in media containing glycerol and oleic acid (Figure 2.6A). We 
therefore sought to investigate whether FBA might regulate a specific balance of 
glycolytic and gluconeogenic metabolism. WT Mtb replicated with glucose as sole 
carbon source and even low concentrations of butyrate enhanced its growth as 
previously reported (de Carvalho et al., 2010) up to 0.4% when butyrate became toxic  
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Figure 2.11. Mtb lacking FBA requires a balanced carbon diet for growth. Growth 
of WT and Δfba was in media containing (A) 0.2% glucose with varying 
concentrations of butyrate and (B) 0.1% butyrate with varying concentrations of 
glucose. Bacteria were cultured in 96-well plates and absorbance was measured at the 
indicated time points. Data are means of triplicate cultures +/- SEM and representative 
of two independent experiments. 
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(Figure 2.11). In contrast, when provided with 0.2% glucose, Δfba required at least 
0.05% butyrate for growth, which was maximal with 0.1% but did not reach that of 
WT suggesting that Mtb’s capacity to metabolize butyrate is limited by FBA 
deficiency.  
With a fixed concentration of 0.1% butyrate, WT growth increased with increasing 
amounts of glucose (Figure 2.11B). Growth of Δfba, however, plateaued with 0.025% 
glucose and was inhibited at concentrations above 0.2%. Inefficient glucose 
metabolism thus limited growth of Δfba in the presence of butyrate suggesting that 
FBA facilitates the efficient catabolism of butyrate by driving glycolysis. Together 
these data imply that the efficiency of glucose metabolism determines Mtb’s capacity 
to co-catabolize butyrate. 
2.3.5 Vulnerability of Mtb to partial FBA depletion depends on the carbon 
source 
Given the in vivo essentiality in acute and chronic mouse infections, our final goal was 
to evaluate to what degree FBA has to be depleted to result in growth inhibition and 
whether this is dependent on the available carbon source. FBA-DUC grew slower than 
WT in media with 0.4% glucose even in the absence of atc (Figure 2.4A) and in 
glucose FBA-DUC was more sensitive to atc-induced growth inhibition than in 
butyrate containing media (Figure 2.12). The reduced growth in glucose-containing, 
atc-free media (Figure 2.4A, 2.13A) was likely due to the low FBA amounts expressed 
in FBA-DUC, which were reduced by approximately 87% compared to WT even in 
the absence of atc (Figure 2.13B). Addition of 6.3 ng/ml atc depleted FBA by 
approximately 97% and abolished growth of FBA-DUC in glucose containing medium. 
In contrast, depletion by 87% or 97% was insufficient to reduce growth of FBA-DUC 
in medium with 0.1% butyrate as the sole carbon source. Addition of 25 ng/ml atc,  
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Figure 2.12. Atc-induced growth inhibition in glucose and butyrate containing 
media. Growth of FBA-DUC without and with indicated amounts of atc in (A) 0.4% 
glucose or (B) 0.1% butyrate. 
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Figure 2.13. Vulnerability of Mtb to FBA depletion depends on the carbon source. 
Growth of WT and FBA-DUC without and with indicated amounts of atc in (A) 0.4% 
glucose or (C) 0.1% butyrate. (B) FBA immunoblot in protein extracts from 0.4% 
glucose cultures on day 15 after atc addition. (D) FBA immunoblot in protein extracts 
from 0.1% butyrate cultures on day 11 after atc addition. PrcB served as loading 
control. 
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which reduced FBA expression below the level of detection by day 11, was required to 
inhibit growth with butyrate. To determine whether higher FBA levels were present at 
earlier timepoints that still corresponded with growth inhibition, we assessed the 
kinetics of FBA depletion of the fba-DUC strain in 0.1% butyrate at various atc 
concentrations, in addition to both growth and survival (Figure 2.14). In this 
experiment, we included a day 1 timepoint and noted that survival was reduced from 
day 1 to 3 in the fba-DUC strain treated with 25 or 500 ng/ml atc. This corresponded 
with a reduction in FBA protein to nearly undetectable levels by day 3 for both 
concentrations. Therefore, FBA protein in this context is depleted by the time at which 
we see growth inhibition, suggesting that FBA does have to be depleted over 97% to 
see an effect on growth. In conclusion, Mtb was more sensitive to FBA depletion 
when grown with glucose as sole carbon source than when metabolizing butyrate 
emphasizing that vulnerability to depletion of an essential protein can be dependent on 
the growth condition. 
2.4 Discussion 
The experiments reported here enhance our understanding of Mtb carbon metabolism 
and are relevant to tuberculosis drug development. Mtb fba has previously been shown 
to be required for growth on standard media (Griffin et al., 2011; de la Paz Santangelo 
et al., 2011) and FBA inhibitors are under development (Capodagli et al., 2014; Daher 
et al., 2010; Fonvielle et al., 2008; Labbé et al., 2012). However, to our knowledge 
only one inhibitor has shown efficacy against live Mtb, at a concentration of 0.6-1.2 
mM in 7H9-OADC broth (Capodagli et al., 2014). Furthermore, it was unknown 
whether FBA is essential for growth or survival of Mtb in vivo. Using a genetic 
approach we evaluated FBA as a potential drug target by assessing its essentiality for 
growth and persistence during mouse infections. Depletion of FBA after establishment  
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Figure 2.14. Kinetics of depletion correlated with growth and survival in 0.1% 
butyrate. (A) Growth and (B) survival of WT and the FBA-DUC strain upon 
exposure to 0, 25, or 500ng/ml atc. Time is in days after atc addition. (C) Western blot 
depicts FBA protein depletion over time. FBA in the FBA-DUC strain has a higher 
molecular weight due to the DAS tag.  
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of chronic infection led to complete clearance of viable Mtb in mouse lungs and 
spleens, which promotes FBA as a potential enzyme for targeting persistent bacilli.  
Unexpectedly, FBA was not essential in all conditions in vitro, and a conditional fba 
mutant was critical to identify conditions in which Δfba could be isolated. This 
deletion mutant was able to replicate when provided with combinations of carbon 
substrates entering metabolism above and below the FBA-catalyzed reaction. Thus, it 
will be crucial to determine the efficacy of FBA inhibitors against live Mtb in carbon 
conditions where Mtb is vulnerable to FBA inactivation in contrast to standard 
mycobacterial liquid culture medium, which contains a combination of glucose and 
glycerol making FBA dispensable.  
Earlier studies have highlighted Mtb’s ability to co-catabolize multiple carbon sources 
in vitro and in macrophages (Beste et al., 2011, 2013; de Carvalho et al., 2010). This is 
in contrast to other bacteria such as E. coli, which exhibits diauxic growth in the 
presence of multiple carbon sources resulting from their sequential metabolism (Görke 
and Stülke, 2008; Kovárová-Kovar and Egli, 1998). Here, we provide further evidence 
for Mtb’s co-catabolism and offer insight into its metabolic regulation. Growth of WT 
Mtb on glucose and on butyrate, which requires β-oxidation for conversion into acetyl-
CoA mimicking the fate of long chain fatty acids, was enhanced in a dose responsive 
manner by addition of the respective other carbon source. Growth of Δfba only 
occurred with two carbon substrates, feeding into either side of the FBA reaction. 
Additionally, deletion of FBA rendered Mtb sensitive to the relative concentrations of 
carbon sources in the medium. In media containing glucose and butyrate, Δfba was 
unable to efficiently utilize glucose to enhance its growth while growth of WT scaled 
with glucose. Metabolism of increasing amounts of butyrate was also restricted shown 
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by Δfba’s limited growth despite the presence of 0.2% glucose. Therefore, FBA 
inactivation resulted in suboptimal co-catabolism of glucose and butyrate. 
The mechanism of death of Δfba in carbon-unbalanced media remains to be 
determined but may be due to buildup of FBA substrates at higher concentrations of 
carbon sources, as well as regulatory mechanisms allowing Mtb to sense carbon levels 
and respond accordingly. Indeed, the inability of Δfba to grow on standard Mtb plate 
medium containing glucose, glycerol and oleic acid was overcome by the addition of 
0.2% additional glucose, which was not required for growth in nearly identical 
medium lacking oleic acid. Interestingly, Δfba survived much better in media 
containing no carbon, suggesting that death is carbon source-dependent. This is not the 
first example of death induced by carbon source; inhibitors were identified that only 
kill Mtb in glycerol, whose use potentially contributed to the buildup of a toxic 
metabolite, methylglyoxal (Pethe et al., 2010). While we did not observe an 
accumulation of a metabolite with the mass over charge ratio of methylglyoxyal (data 
not shown), this metabolite is difficult to detect, and it is possible that this or other 
metabolic accumulations we did observe could lead to toxicity.  
Accumulation of sugar phosphates including the FBA substrate fructose-1,6-
bisphosphate (FBP) has also been implicated in growth inhibition. Inactivation of FBA 
in E. coli prevented growth with glucose but not with glycerol and succinate as carbon 
substrates (Böck and Neidhardt, 1966a, 1966b). Suppressor mutations that prevented 
FBP buildup allowed for growth on glucose (Schreyer and Bock, 1973). With our 
metabolite extraction protocol we did not detect FBP, however other sugar phosphates 
including hexose-P, sedoheptulose-P and pentose-P increased dramatically in Δfba 
cultured on glucose, while triose-P and PEP accumulated on glycerol. The 
accumulation of these metabolites was not observed when both glucose and glycerol 
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were available to Δfba, except for the triose-P pools, which remained elevated but 
much less than in the glycerol condition. It is thus possible that the accumulation of 
phosphorylated metabolites is cause for the death of Δfba in conditions where 
glycolytic and gluconeogenic carbon flow is unbalanced, such as with single carbon 
substrates or in mixes with an abundance of a glycolytic or gluconeogenic substrate.  
To better understand the mechanism of death in single carbon sources, future work 
could include transcriptomics analysis to identify stress response pathways that are 
upregulated in response to glucose, glycerol or butyrate. Also, it may be valuable to 
plate dense culture of the fba KO onto single carbon sources, to screen for suppressor 
mutations. To promote the generation of mutations, a transposon mutagenesis 
approach may be worthwhile. This could identify pathways involved in the generation 
of stresses that lead to growth inhibition or death in single carbon sources. 
While it is unknown whether a loss-of-function mutation could allow for growth of 
FBA-deficient bacteria on single carbon sources, we have isolated a strain lacking 
FBA that grows on OADC-containing media without the addition of extra glucose. 
Interestingly, this strain has a loss of function mutation in a probable succinate 
dehydrogenase membrane subunit, a TCA cycle enzyme complex. This mutation 
could cause a slow down of TCA cycle activity, leading to reduced NADH production 
and potentially less oxidative stress. Additionally, this mutation could increase 
succinate levels, which could provide protective functions for the cell as has been 
demonstrated for hypoxic conditions (Eoh and Rhee, 2013). Preliminary work (not 
shown) suggests that this mutation does not grant growth advantages in various 
mixtures of glucose and acetate compared to the parent knockout strain. It would be of 
interest in the future to define the sensitivity of Δfba and Δfba-OADC resistant strain 
to various concentrations of oleic acid, as opposed to OADC supplement. 
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Metabolomics experiments comparing the intracellular metabolites of Δfba and Δfba-
OADC resistant strains in oleic acid may reveal differences in accumulation of 
succinate or other metabolites. However, most important is to determine whether this 
mutation could allow for growth of Mtb lacking fba in the mouse model. 
How potent would an FBA inhibitor need to be to affect Mtb growth? We measured 
the vulnerability of Mtb to FBA depletion in single glycolytic and gluconeogenic 
carbon sources where FBA is essential. Although depleting FBA by 97% did not 
affect growth with butyrate as sole carbon source, it prevented growth with glucose 
and 87% inhibition was sufficient to reduce growth with glucose. These data reveal a 
differential susceptibility of Mtb to FBA depletion, depending on the available carbon 
source. Antibiotic targets vary widely in how much inhibition is required to stop 
replication or induce death and not all effective drug targets are highly vulnerable to 
inhibition (Wei et al., 2011). Specific target-drug interactions can contribute to the 
efficacy of a compound. We cannot predict how effectively FBA must be depleted to 
abolish replication in vivo, but the WT-like phenotype of FBA-DUC without doxy 
suggests that 13% of WT FBA levels are sufficient for normal growth and persistence 
in mice. The fast killing of Mtb following further FBA depletion in mouse lungs and 
spleens suggests that it is an effective target during acute and chronic mouse infections. 
During infections FBA may also have an additional, metabolism-independent function 
in Mtb’s interaction with the host as it can be secreted and bind to human plasminogen 
(de la Paz Santangelo et al., 2011). 
The requirement of FBA for growth and persistence in mice suggests that in vivo Mtb 
either faces single carbon sources or lacks access to the growth permissive ratio of 
carbon sources that can compensate for the lack of FBA. This is likely due to an 
abundance of fatty acids and lipids which are predominant carbon sources available to 
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Mtb in vivo (Marrero et al., 2010; Munoz-Elias and McKinney, 2005; Pandey and 
Sassetti, 2008; Segal and Bloch, 1956). It is unknown if FBA is essential for growth 
and persistence of Mtb in humans; experimental animal models that more closely 
mimic human TB pathology (Véronique Dartois, 2010) would help address this 
question. Given that human granulomas contain lipid-rich foamy macrophages and 
build up lipids in the caseum (Kim et al., 2010; Peyron et al., 2008), it is plausible that 
Mtb requires FBA also during human infection. 
2.5 Materials and Methods 
2.5.1 Ethics statement 
Mouse studies were performed following National Institutes of Health guidelines for 
housing and care of laboratory animals and performed in accordance with institutional 
regulations after protocol review and approval by the Institutional Animal Care and 
Use Committee of Weill Cornell Medical College (protocol # 0601-441A, Conditional 
Expression of Mycobacterial Genes). 
2.5.2 Strains, media and culture conditions 
Mycobacterium tuberculosis (Mtb) H37Rv strains were grown in Middlebrook 7H9 
liquid media containing 0.5% bovine serum albumin fraction V, 0.2% glucose, 0.2% 
glycerol, 0.085% NaCl, and 0.05% tyloxapol without shaking in 5% CO2 at 37°C. For 
carbon-defined growth curves, Mtb was cultured in Sauton’s base media modified to 
be carbon-limited, containing 0.05% potassium phosphate monobasic, 0.05% 
magnesium sulfate heptahydrate, 0.2% citric acid, 0.005% ferric ammonium citrate, 
0.05% ammonium sulfate, 0.0001% zinc sulfate, and 0.05% tyloxapol at pH 7.4. For 
solid media, Middlebrook 7H10 media with 0.5% glycerol and 10% Middlebrook 
OADC supplement (final concentration of 0.5% bovine serum albumin fraction V, 
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0.2% glucose, 0.085% NaCl, 0.006% oleic acid, 0.0003% catalase) or self-made 
ADNaCl (final concentration of 0.5% bovine serum albumin fraction V, 0.2% glucose, 
0.085% NaCl) was used. Carbon sources glucose, glycerol, sodium acetate and butyric 
acid, were added at indicated concentration (%wt/vol or %vol/vol, depending on 
stock). When appropriate, hygromycin B (50 mg/ml), streptomycin (10 mg/ml), 
kanamycin (25 mg/ml), and/or zeocin (25 mg/ml) were added. Anhydrotetracycline 
(atc) was added at the indicated concentrations and replenished at half the initial 
concentration in liquid cultures every 4-5 days for growth curves but not vulnerability 
assays. For survival assays, bacterial culture samples were taken from growth curve 
cultures at the time-points indicated and plated for CFU. For metabolomic profiling, 
Mtb was seeded at OD580~1 on 0.22 mM nitrocellulose filters (1ml per filter) and 
cultured on Middlebrook 7H10 agar medium containing 0.5% bovine serum albumin 
fraction V, 0.085% NaCl, 0.2% glucose, and 0.2% glycerol for 5 days. Filters were 
then transferred to similar plates with defined carbon sources: 0.2% glucose, 0.2% 
glycerol, or both together, each at 0.2%. Mtb was harvested 24 hours later by 
metabolic quenching in cold acetonitrile:methanol:H2O (40:40:20) and mechanically 
lysed using a bead beater as described (de Carvalho et al., 2010; Marrero et al., 2010).  
2.5.3 Generation of mutant strains 
M. tuberculosis H37Rv was transformed with a plasmid expressing fba under the 
control of a strong promoter P1 (Psmyc) that integrates into the phage attL5 site in the 
Mtb genome (Ehrt et al., 2005). In this fba merodiploid strain deletion of native fba 
was achieved by allelic exchange using specialized transducing phage phAE87 as 
previously described (Marrero et al., 2010). After confirming removal of native fba by 
Southern blot, replacement transformations of the attL5 insets were performed to 
generate FBA-DUC and Δfba. In FBA-DUC, fba contained a C-terminal DAS+4 tag 
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and a plasmid in the phage tweety site that allowed inducible expression of SspB as 
described (Kim et al., 2013). In Δfba the attL5 site carries a kanamycin-resistant 
plasmid not containing fba. All plasmids were constructed using Gateway Cloning 
Technology (Invitrogen) using BP and LR recombinase reactions following the 
manufacturers instructions. The complemented mutant is Δfba transformed with a 
plasmid that integrates in the attL5 site expressing fba from the P1 promoter. 
2.5.4 Whole genome sequencing 
Sequencing of fba KO and fba OADC-resistant strain DNA was performed in 
collaboration with Jim Sacchettini and Tom Ioerger at Texas A&M. The fba KO 
contains a deletion of fba as well as the following mutations compared to the WT 
H37Rv parent strain: Rv2226 –GC in res 373/513; Rv1968/mce3C I241I; Rv2621c 
V47G; Rv2934/ppsD –T in res 642/1827; and Rv3487c/lipF V15L. The fba OADC-
resistant strain has the following mutations in addition to those found in the fba KO 
strain: Rv0249c W31* and Rv2347c/hrcA A123V.  
2.5.5 Metabolomics using Liquid Chromatography-Mass Spectrometry  
M. tuberculosis metabolites were separated and detected in a Agilent Accurate Mass 
6220 TOF coupled to an Agilent 1200 Liquid Chromatography system using a Cogent 
Diamond Hydride Type C column (Microsolve Technologies) using solvents and 
configuration as described (Eoh and Rhee, 2013). Metabolites were quantified by 
standard curves generated with authentic chemicals spiked into homologous 
mycobacterial lysates. Quantified metabolite concentrations were normalized to 
bacterial biomass of individual samples determined by measuring residual protein 
content (BCA Protein Assay kit; Pierce).  
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2.5.6 Immunoblot analysis for vulnerability assay  
Protein extracts were prepared from bacterial pellets from 30 ml cultures at indicated 
time points in specified media. Briefly, cultures were washed with phosphate buffered 
saline (PBS), 0.05% Tween 80 and resuspended in 1 ml PBS, 1x protease inhibitor 
cocktail (Roche). Cells were lysed by bead beating three times at 4500 rpm for 30 
seconds with 0.1 mm Zirconia/Silica beads. Beads and cell walls were removed 
through centrifugation (11000 x g/ 10 min/ 4°C) and the supernatant was filtered 
through a 0.2 mm SpinX column (Corning). Lysate protein concentrations were 
determined using a DC Protein Assay Kit (Bio-Rad). For immunoblots 20-0.02 mg 
protein extracts were separated by SDS-PAGE, transferred to nitrocellulose 
membranes and probed overnight with rabbit antisera FBA (de la Paz Santangelo et al., 
2011) (1:2000 dilution in 1:1 PBS/Odyssey Blocking Buffer (LI-COR Biosciences), 
0.1% Tween20) or PrcB (1:18,000 dilution in 1:1 PBS/Odyssey Blocking Buffer (LI-
COR Biosciences), 0.1% Tween20).  As secondary antibody IRDye 680 Donkey anti-
Rabbit IgG(H+L) (LI-COR Biosciences) was used. Proteins were detected using the 
Odyssey Infrared Imaging System (LI-COR Biosciences). 
2.5.7 Mouse and macrophage infections 
Female C57BL/6 mice (Jackson Laboratory) were infected by aerosol using an 
inhalation exposure system (Glas-Col) and early-log-phase M. tuberculosis cultures as 
single-cell suspensions in PBS to deliver 100 to 200 bacilli per mouse. Doxycycline-
containing food (2000 ppm, Research Diets) was given to mice starting at the 
indicated time-points. Serial dilutions of lungs and spleens homogenates were cultured 
on 7H10 plates containing ADNaCl to determine CFU at the indicated time points. 
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The left lobe of each lung was fixed in 10% buffered formalin, further processed for 
histopathology and stained with hematoxilyn and eosin. We isolated and infected bone 
marrow-derived mouse macrophages as previously described (Vandal et al., 2008).  
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CHAPTER 3 
THE ROLE OF MALATE SYNTHASE IN PATHOGENICITY OF 
MYCOBACTERIUM TUBERCULOSIS 
 
3.1.  Introduction 
The glyoxylate shunt is an attractive pathway to target with novel anti-tuberculosis 
therapeutics, as it is required for Mycobacterium tuberculosis (Mtb) growth on fatty 
acids and is not functional in humans. Furthermore, Mtb deficient in isocitrate lyase 
(ICL), the first enzyme in the pathway, is drastically attenuated in the mouse model of 
infection. The interpretation of this phenotype is complicated by the fact that ICL also 
participates in the methylcitrate cycle, a propionyl-CoA detoxification pathway. 
However, the second enzyme in the glyoxylate shunt, malate synthase (MS), is not 
known to have a secondary metabolic function. In Mtb, the only known malate 
synthase is encoded by the gene glcB. Here, to evaluate malate synthase as a drug 
target and to enhance our understanding of the importance of the glyoxylate shunt in 
Mtb metabolism, we generated glcB knockdown and knockout strains to determine the 
requirement for malate synthase in vitro and in the mouse model.   
3.2 Background 
Malate synthase (MS) is an enzyme that converts glyoxylate and acetyl-CoA to malate 
and CoA. This enzymatic step is the second in the glyoxylate shunt after the 
conversion of isocitrate to glyoxylate and succinate by isocitrate lyase (ICL). The 
glyoxylate shunt is critical for growth of bacteria in fatty acid carbon sources, as it 
allows for retention of acetyl-CoA-derived carbon for biomass by preventing carbon 
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loss in the form of CO2 following the canonical TCA cycle. The glyoxylate shunt has 
been implicated in the pathogenesis of several organisms, including Candida albicans, 
Psuedomonas aeruginosa, and Rhodococcus fascians. However, Salmonella 
typhimurium, Yersinia pestis, and Aspergillus fumigatus were unaffected in their 
virulence upon glyoxylate shunt disruption (Dunn et al., 2009).  
Malate synthase commonly occurs in two isoforms, malate synthase A (MSA) found 
in plants, yeast, and prokaryotes and malate synthase G (MSG), found exclusively in 
prokaryotes (Lohman et al., 2008; Smith et al., 2003). The nomenclature derives from 
the carbon source that regulates each enzyme in E. coli, which contains both isoforms; 
MSA is regulated during growth in acetate, whereas MSG is regulated during growth 
on glycolate. MSGs are larger (~80kDa) than MSAs (~60kDa) and share ~65% 
identity within their class and ~18-20% identity with MSAs. In placental mammals, 
the presence of a glyoxylate pathway is doubtful, as the genetic region with malate 
synthase homology is a pseudogene (Kondrashov et al., 2006). Furthermore, the ICL 
gene is absent in animals except for nematodes, which express a fused ICL-MS gene. 
Therefore, it may be possible to target bacterial malate synthase without interfering 
with human metabolism. 
Mtb expresses a single malate synthase G, an 80.4 kDa protein 741 amino acids long 
encoded by the gene glcB (rv1837c) (Figure 3.1).  Genetic studies are lacking because 
multiple attempts to directly knock out glcB via allelic exchange were unsuccessful 
(Merkov, 2006). Deep-sequencing analysis assessing the ability of transposon 
insertions to occur within the glcB locus suggest that glcB is essential in minimal 
media but not in rich media (Griffin et al., 2012; Zhang et al., 2012). The crystal 
structure for Mtb MS is available, and enzymatic assays have demonstrated that the  
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Figure 3.1. Schematic depicting the role of malate synthase in Mtb central carbon 
metabolism. The malate synthase (MS) step is highlighted in red and the entry points 
of carbon sources glucose (6 carbons), acetate (2 carbons), fatty acids (4+ carbons), 
glycerol (3 carbons) and propionate (3 carbons) are in black boxes. Pathways 
involving steps non-depicted steps are in dotted lines. The asterisk indicates the 
enzymatic step catalyzed by methylmalonyl-CoA mutase, a vitamin B12-dependent 
enzyme.  
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enzyme does have malate synthase activity (Smith et al., 2003). Further efforts to 
understand the mechanism of the reaction have been undertaken (Bauzá et al., 2014; 
Quartararo and Blanchard, 2011). The enzyme is thought to exist either as a monomer 
or a dimer, with amino acid residues Asp-633, Glu-434, and Asp-462 and a catalytic 
Mg2+ ion playing probable roles in its enzymatic function (Kumar and Bhakuni, 2010; 
Smith et al., 2003). MS from Mtb has ~60% identity to the MSG of Corynebacterium 
glutamicum and Escherichia coli. Unlike isocitrate lyase, malate synthase does not 
appear to be largely upregulated in Mtb within macrophages, mice, in microaerophilic 
conditions, or in carbon sources acetate or palmitate (Rohde et al., 2012; Schnappinger 
et al., 2003; Shi et al., 2010; Smith et al., 2003; Wayne and Lin, 1982). The only 
carbon source reported to increase MS expression was glycolate, and this was only a 
2-fold upregulation (Smith et al., 2003). Furthermore, unlike in C. glutamicum, the 
ICL and MS genes are located in separate regions of the genome. Therefore it appears 
that regulation of the glyoxylate shunt occurs primarily through regulation of ICL 
expression, and that regulatory mechanisms affecting expression of ICL do not also 
regulate MS.  
Outside of its enzymatic function, MS may also play a role in Mtb cell adhesion to 
host proteins. MS is predominately cytosolic, but is also secreted. MS can localize to 
the cell wall, and has been shown to bind host laminin and fibronectin (Kinhikar et al., 
2006). A 15 amino acid C-terminal tail unique to the Mtb MS was shown to play a role 
in this adhesion. MS is currently being developed as an antigen for testing of latent 
tuberculosis in rheumatoid arthritis patients, as the body develops a Th1-specific 
response to the MS antigen (Silva et al., 2014).  
While genetic studies are lacking for the Mtb malate synthase, the characterization of a 
MS knockout in M. smegmatis was described in a dissertation by L. Merkov (Merkov, 
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2006). The M. smegmatis MS protein is homologous to the Mtb protein, with an 
identity of 80%. Surprisingly, this M. smegmatis glcB knockout grew on media 
containing single carbon sources glucose, acetate, propionate, butyrate, and valerate. 
Additional knock out of ald, a gene encoding an alanine dehydrogenase that could 
potentially act as a glyoxylate aminase, did not prevent growth on acetate. A 
transposon mutagenesis screen in the ΔglcBΔald background for mutants that could 
not grow on acetate uncovered an alternative glyoxylate metabolic pathway (the d-
glycerate pathway) involving glyoxylate carboligase (encoded by the gene gcl). 
Deletion of glcB and gcl in the same strain resulted in inability of M. smegmatis to 
grow on acetate (2C), butyrate (4C), and hexanoate (6C), and this growth was restored 
upon complementation with the Mtb glcB. However, the ΔglcBΔgcl mutant grew on 
propionate (3C), suggesting that glyoxylate metabolism is not required for propionyl-
CoA utilization in M. smegmatis. Importantly, homologs for gcl and other glycerate 
pathway enzymes are absent in Mtb (Chopra et al., 2014).  
Research concerning the Mtb isocitrate lyase (ICL), the first enzyme of the glyoxylate 
shunt, has been far more extensive than for malate synthase. Genetic knockout and 
knockdown studies targeting the genes encoding ICL (icl1 and icl2) have 
demonstrated that ICL is required for establishment and maintenance of infection in 
mice (Blumenthal et al., 2010; McKinney et al., 2000; Munoz-Elias and McKinney, 
2005). Subsequent studies have revealed that a secondary function outside of the 
glyoxylate shunt could contribute to this dramatic mouse phenotype. ICL also acts as a 
methylisocitrate lyase, an enzyme in the methylcitrate pathway that is involved in 
propionate detoxification (Gould et al., 2006; Upton and McKinney, 2007). Growth of 
ICL-deficient Mtb is inhibited by propionate, even in the presence of other carbon 
sources. Furthermore, loss of ICL results in accumulation of methylcitrate cycle 
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intermediates in glucose, acetate, and especially in propionate (Eoh and Rhee, 2014). 
In 0.05% propionate and 0.2% glucose, growth is rescued by addition of 10µg/ml 
vitamin B12, a cofactor required for the function of methylmalonyl CoA mutase, an 
enzyme in the methylmalonyl-CoA pathway (Eoh and Rhee, 2014). This is an 
alternative propionyl-CoA metabolic pathway and alleviates propionate toxicity in the 
absence of a functional methylcitrate cycle (Savvi et al., 2008). The lack of mouse 
phenotype of a prpDC mutant, which lacks methylcitrate synthase and dehydratase 
activity in the methylcitrate cycle, suggests that Mtb either has access to vitamin B12 
within the host which alleviates propionate toxicity via the methylmalonyl pathway, 
and/or that Mtb requires prpDC to make toxic metabolites from propionate (Muñoz-
Elías et al., 2006; Savvi et al., 2008; Upton and McKinney, 2007). Indeed, a lack of 
methylisocitrate lyase activity caused by ICL deficiency would lead to an 
accumulation of methylcitrate and methylisocitrate, two potentially toxic metabolites 
that should not be generated in the prpDC knockout. Therefore, it is possible that a 
lack of methylisocitrate lyase activity, a lack of isocitrate lyase activity, or both 
together cause death of ICL-deficient Mtb in the mouse model.  
In vitro studies have emphasized a role for ICL in Mtb survival in several contexts 
relevant to the host environment. During human infection, Mtb encounters a hypoxic 
environment potentially rich in fatty acids and other lipids. In hypoxia in vitro, Mtb 
adopts a bifurcated, reductive TCA cycle, whose end product is succinate (Eoh and 
Rhee, 2013; Watanabe et al., 2011). In this context, ICL is upregulated and plays a 
role in succinate generation, which helps Mtb adapt to hypoxia and maintain 
membrane potential, appropriate ATP levels, NAD+/NADH ratio, and metabolite 
levels to prevent death (Eoh and Rhee, 2013). During exposure to 0.2% acetate or 
0.2% propionate, ICL-deficient Mtb also died, and this death was rescued up to 3 days 
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by addition of vitamin B12, suggesting that a lack of a functional methylcitrate cycle 
was the cause of death. ICL also plays a role in broad-spectrum antibiotic resistance, 
as Δicl1Δicl2 bacteria were much more susceptible to killing by streptomycin, 
isoniazid, and rifampicin (Nandakumar et al., 2014). Addition of antioxidants thiourea 
or tempol to the bacteria enhanced viability of Δicl1Δicl2 in these antibiotics, 
suggesting that ICL could also play a role in alleviating or preventing oxidative stress. 
Whether Mtb lacking malate synthase would also have similar phenotypes to ICL-
deficient Mtb in these contexts remains to be determined.  
There has been interest in development of malate synthase inhibitors as novel anti-TB 
therapeutics. Phenyl-diketo acid (PDKA) inhibitors, which contain structural 
similarities to glyoxylate, have shown efficacy at inhibiting growth of Mtb H37Rv in 
acetate and in glucose (Krieger et al., 2012). One specific inhibitor had an MIC99 of 2 
µM in acetate and 8 µM in glucose against H37Rv in vitro, and reduced the ability of 
Mtb to establish infection in mice. Furthermore, overexpressing glcB in strains treated 
with the inhibitor raised the MIC in both acetate and glucose, but did not raise the 
MIC in strains treated with rifampicin, suggesting that the inhibitor has on-target 
effects in both conditions. These data support a role for malate synthase for growth in 
a variety of carbon sources, although the reason for its requirement in glucose is 
unclear.   
We aimed to use genetic methods to further validate malate synthase as a drug target 
in Mtb and to better understand the role of the glyoxylate shunt during infection. In 
doing so, we uncovered a role for malate synthase in virulence and in Mtb fatty acid 
resistance.  
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3.3 Results 
3.3.1  Generation of the malate synthase knockdown strain 
Due to conflicting reports of glcB essentiality and a described inability to directly 
generate a glcB knockout strain, we first introduced a second copy of glcB into the 
attL5 phage integration site to generate a merodiploid strain. We transformed this 
merodiploid strain with a temperature-sensitive knockout plasmid containing a 
hygromycin resistance cassette flanked with DNA regions homologous to those 
surrounding glcB in the native locus. After selecting for double crossover a few 
colonies were obtained. These were confirmed to contain the expected deletion by 
Southern blot (Figure 3.2A-B). Candidate number one was used for the generation of 
all glcB mutants described here and will be referred to as the glcB att site mutant. 
We then generated a dual control (DUC) strain, in which both transcription of glcB 
and proteolysis of MS were controlled by addition of anhydrotetracycline (atc) (Kim 
et al., 2011). After confirming that atc addition reduced expression of MS to 
undetectable levels (Figure 3.2C), we tested growth of glcB-DUC in media with single 
carbon sources plus and minus atc (Figure 3.3). As expected, glcB-DUC could not 
grow plus atc in acetate alone. However, glcB-DUC plus atc could grow in glucose 
alone with a slight growth defect compared to WT. This suggested that glcB is not 
essential for growth in all conditions.  
3.3.2 Generation of the glcB knockout strain (ΔglcB) 
To determine whether glcB is essential on plate media, we attempted to generate a 
glcB knockout by replacement transformation of the glcB att-site mutant with a 
plasmid lacking glcB. Successful transformants lose the glcB plasmid but gain 
kanamycin resistance. We tried plating on conditions identical to those used to  
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Figure 3.2. Confirmation of the generation of the glcB conditional knockdown 
and knockout strains. (A) Southern blot design showing the genomic locus of glcB 
and the same locus after successful replacement of 2140 bps of glcB with a 
hygromycin resistance cassette via homologous recombination with a knockout 
plasmid. (B) Southern blot showing three candidates derived from the merodiploid 
(Mero) strain which express glcB at the attL5 site but lack a functional glcB in the 
native locus, as indicated by the expected shift in band size. Candidate 1 was used for 
generation of all glcB mutant strains. (C) Western blot showing malate synthase (MS) 
protein expression level of wildtype (WT), ΔglcB (KO), glcB complemented (C), and 
glcB-dual control (DUC) strains minus or plus anhydrotetracycline (atc). (D) 7H10 
agar plates containing 10% OADC supplement do not support growth of the ΔglcB 
while plates containing 10% ADNaCl supplement support growth of small, slow-
growing colonies. OADC contains oleic acid and catalase, while ADNaCl does not.  
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Figure 3.3. Silencing of glcB inhibits Mtb growth in acetate but does not prevent 
growth in glucose. Wildtype (WT) and glcB-DUC strains were grown plus and minus 
500ng/ml atc in (A) 0.4% glucose, (B) 0.1% acetate, or (C) no carbon in minimal 
carbon-defined media.  
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generate the fba knockout (see Chapter 2). Similar to the fba mutant, no colonies grew 
on standard Mtb kanamycin plates containing 10% OADC and 0.5% glycerol, while 
colonies did appear on kanamycin plates containing 10% ADNaCl and 0.5% glycerol. 
OADC supplement contains oleic acid and catalase, while ADNaCl does not. However, 
unlike with the fba knockout, addition of 0.2% extra glucose did not allow for growth 
on plates containing OADC (not shown). This suggested that glcB is not essential for 
Mtb growth on plates lacking oleic acid and catalase.  
We selected several glcB knockout candidates from the ADNaCl plate and 
successfully grew them in standard Mtb liquid media containing 0.2% glucose and 
0.2% glycerol. The glcB knockout candidate (ΔglcB) we chose for this study lacked 
MS expression and recapitulated the OADC sensitivity when re-cultured on agar 
plates (Figure 3.2C-D). Growth of ΔglcB takes roughly 40 days to appear on plates. In 
collaboration with Dr. Jim Sacchettini and Dr. Tom Ioerger, the genomic DNA of the 
glcB knockout was sequenced and confirmed to have the expected glcB deletion. 
ΔglcB also had a point mutation in embC (N693K), a gene involved in synthesis of 
cell wall component arabinan, and a 5.5 kilobase deletion in ppsA and ppsB, genes 
involved in biosynthesis of phthiocerol dimycocerosate (PDIM), a cell wall lipid. 
Mutations in PDIM are common in Mtb strains passaged in vitro in laboratory 
conditions (Domenech and Reed, 2009). To rule out effects these secondary mutations 
may have on phenotypes we observed, we generated a ΔglcB complemented strain 
derived from the ΔglcB strain, in which glcB is expressed at the attL5 site from its 
native promoter (Figure 3.2C). We used this strain as a control in subsequent 
experiments throughout this chapter.  
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3.3.3 Malate synthase is essential for Mtb growth and persistence in the mouse  
To determine the importance of malate synthase for establishment and maintenance of 
infection in an animal model, we infected mice with WT Erdman, ΔglcB, and glcB-
DUC Mtb strains. Mice infected with glcB-DUC were fed mice doxy food to silence 
glcB at different timepoints during and after establishment of infection (Figure 3.4). 
We found that glcB was required for both growth and maintenance of infection in 
mouse lungs and spleens. Furthermore, silencing glcB after establishment of infection 
reduced lung lesion size by day 113 post-infection. These data showed that targeting 
MS can kill Mtb in vivo and validates further work on MS inhibitors.  
3.3.4 Malate synthase is dispensable for growth in glucose and glycerol, but not 
in acetate, fatty acids, and cholesterol 
To better understand the conditional essentiality of the glcB knockout, we assessed 
growth of ΔglcB in various single carbon sources. Similar to growth of the glcB-DUC 
strain plus atc, growth of ΔglcB was achieved in glucose but not acetate (2-carbon). 
ΔglcB also grew in glycerol but failed to grow in fatty acids propionate (3-carbon) and 
butyrate (4-carbon) (Figure 3.5). We also tested growth in media containing 0.01% 
cholesterol, a physiologically-relevant carbon source that is broken down into 
pyruvate, acetyl-CoA, and propionyl-CoA, as described (Griffin et al., 2012) (Figure 
3.6A). While the WT enhanced its growth in cholesterol, ΔglcB did not. This 
demonstrated that malate synthase is essential for growth on acetate, cholesterol, and 
fatty acids, including carbon sources that feed into the methylcitrate cycle.  
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Figure 3.4. Malate synthase is required for growth and survival of Mtb in the 
mouse model. (A) Lung and (B) spleen bacterial burden over time in mice infected on 
day 0 with WT or the glcB-DUC Mtb strains. Organ homogenates were plated on 
7H10 ADNaCl plates. Mice infected with glcB-DUC were given doxy mouse chow on 
the indicated days. There were no detected atc-resistant revertants. Similar results for 
the early timepoints were observed in a short-term (28-day) infection. Data are means 
+/-SD. (C-D) Gross pathology and H&E staining of lung sections from mice infected 
with glcB-DUC on day 35 day 113 post-infection. 
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Figure 3.5.  Malate synthase is required for growth in acetate, propionate, and 
butyrate but not in glucose or glycerol. The WT, ΔglcB, ΔglcB complemented 
(comp), and Δicl1Δicl2 strains were grown in single carbon sources (A) 0.4% glucose, 
(B) 0.4% glycerol, (C) 0.1% propionate, (D) 0.1% acetate, (E) 0.1% butyrate, or (F) 
no carbon, in carbon-defined minimal media. Data are representative of at least two 
experiments.  
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Figure 3.6. Growth of ΔglcB is inhibited by cholesterol. (A) Growth of WT 
Erdman and ΔglcB in Sassetti base medium, plus or minus 0.01% cholesterol. (B) 
Growth of WT Erdman and ΔglcB in Sassetti base medium plus 0.01% cholesterol 
with or without 0.2% glucose. Data are representative of two experiments. 
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3.3.5 Acetate alters growth of ΔglcB in glucose in a dose-dependent manner 
Mtb is thought to encounter fatty acids and other lipids within the host environment, 
but may also encounter carbon sources such as carbohydrates. In order to mimic the 
effect of exposure to fatty acids we chose to use acetate as a carbon source, as it does 
not have solubility issues. Similar to fatty acids, acetate enters the TCA cycle after 
conversion to acetyl-CoA. In order to determine whether presence of a carbohydrate 
(glucose) could rescue growth in acetate, we performed 96-well plate growth assays 
and growth curves in flasks in which glucose concentration was kept constant (0.2%) 
while acetate concentration varied (Figure 3.7, 3.8A). WT Mtb is known to co-
catabolize carbon sources glucose and acetate to enhance its growth, which is what we 
observed (de Carvalho et al., 2010a). We also observed that growth of ΔglcB was 
enhanced by low concentrations of acetate. However, acetate was growth inhibitory 
for the ΔglcB at a concentration of 0.1% and higher, whereas acetate did not become 
growth inhibitory for the WT until 0.4%. Growth of ΔglcB in media containing 0.01% 
cholesterol was also not rescued by 0.2% glucose (Figure 3.6B). These data showed 
that ΔglcB is able to co-catabolize glucose and acetate at lower acetate concentrations 
to enhance its growth. However, high acetate concentrations and 0.01% cholesterol 
have a dominant negative effect, as glucose could not rescue growth of ΔglcB in these 
conditions.  
3.3.6 ΔglcB slowly in acetate, and glucose exacerbates this phenotype 
To understand whether acetate kills Mtb lacking malate synthase and whether glucose 
can rescue this effect, we determined viability with colony forming unit (CFU) assays 
in 0.025% acetate, 0.2% acetate, 0.2% acetate plus 0.2% glucose, and 0.2% plus 0.4%  
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Figure 3.7. Growth of Mtb lacking glcB is enhanced or inhibited by acetate, 
depending on the concentration.  Growth of (A) WT or (B) ΔglcB strains in 0.2% 
glucose supplemented with the indicated concentrations of acetate. (C) Comparison 
of WT and ΔglcB growth on day 27 at varying acetate concentrations. Assays were 
performed in 96-well plate format and data are means +/- SEM of triplicate cultures 
with carbon-defined minimal media.  
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Figure 3.8. ΔglcB growth and survival is impaired by high but not low acetate 
concentrations. (A) WT Erdman and ΔglcB were grown in T25 flasks in carbon-
defined minimal medium plus the indicated carbon sources. (B) ΔglcB was exposed 
to the indicated carbon source(s) in T25 flasks and aliquots were plated for CFU at 
the indicated time points. Survival data are the means +/- SD of triplicate cultures.  
 
  
	  	  103 
glucose (Figure 3.8B). We found that survival of ΔglcB bacteria was dependent on the 
concentration of acetate in the media and that death in 0.2% acetate was exacerbated 
by glucose. In media with no added carbon, ΔglcB persisted. A concentration of 
0.025% acetate led to ~½ log10 killing by day 20, while 0.2% acetate resulted in ~1 
log10 killing. Addition of 0.2% glucose to 0.2% acetate resulted in over 2 log10 drop in 
CFU and addition of 0.4% glucose to 0.2% acetate resulted in a ~3 log10 reduction by 
day 20. These data showed that acetate exposure impairs survival of ΔglcB in the 
absence of glucose, and that glucose enhances killing in 0.2% acetate in a 
concentration-dependent manner.   
3.3.7 ΔglcB experiences metabolic perturbations in acetate 
In order to confirm that glcB deletion inhibited malate synthase activity, and to 
determine the metabolic changes associated with growth-permissive and non-
permissive conditions, we used a metabolomics approach. WT, ΔglcB, and ΔglcB 
complemented strains were grown on filters and exposed to 0.2% glucose, 0.2% 
acetate, 0.025% acetate plus 0.2% glucose or 0.2% acetate plus 0.2% glucose for one 
day. Analysis of the metabolite pool sizes in bacterial lysates by liquid 
chromatography-mass spectrometry (LC-MS) indicated drastic changes in ΔglcB 
exposed to high levels of acetate (Figure 3.9 and Table 3.1).  
Glyoxylate, a substrate for the malate synthase reaction, accumulated in the knockout 
compared to WT and the complemented strain in all conditions tested. Compared to 
WT, ΔglcB accumulated glyoxylate 9.9-fold more in 0.2% glucose, 37.0-fold more in 
0.2% acetate, 21.2-fold more in 0.025% acetate plus 0.2% glucose, and 73.2-fold more 
in 0.2% acetate plus 0.2% glucose. Accumulations were also observed for other 
metabolites in 0.2% acetate plus 0.2% glucose, including alpha-ketoglutarate, cis- 
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Figure 3.9. Metabolic profiling reveals accumulation of metabolites upstream of 
MS reaction and depletion of downstream metabolites in acetate.  Liquid 
chromatography mass spectrometry (LCMS) analysis of bacterial lysates after 
bacterial exposure to 0.2% glucose (Gluc), 0.2% acetate (Ace), 0.2% glucose plus 
0.025% acetate (Low), or 0.2% glucose plus 0.2% acetate (High) for one day. 
Metabolite levels are reported as nmol per mg protein, except in the case of (iso)citrate 
reported in ion counts (IC) per mg protein (these ion counts were outside the range of 
the standards). G6P is glucose 6-phosphate, F6P is fructose 6-phosphate, DHAP is 
dihydroxyacetone phosphate, G3P is glyceraldehyde 3-phosphate, PEP is 
phosphoenolpyruvate. Statistical analysis was performed using students two-tailed T-
test *p≤0.05 **p≤0.005. 
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Table 3.1. ΔglcB fold change compared to WT. Bold values are statistically 
significant.  
   
Metabolite 
0.2% 
glucose 
(Gluc) 
0.2% 
acetate 
(Ace) 
0.025% 
acetate + 
0.2% 
glucose 
(Low) 
0.2% 
acetate + 
0.2% 
glucose 
(High) 
alanine 1.33 -1.70 1.07 1.99 
α-ketoglutarate 2.36 2.76 1.30 12.87 
aspartate -4.41 -9.49 -4.80 -73.34 
cis-aconitate 1.43 1.24 1.19 1.66 
citrate/isocitrate 1.05 1.21 -1.14 1.56 
fumarate -1.38 -3.86 -2.00 -2.37 
glycine 1.20 7.20 1.00 7.20 
glyoxylate 9.87 36.96 21.23 73.21 
hexose-P -1.48 -3.42 -3.13 -1.40 
malate -1.28 -13.93 -2.39 -7.15 
methylcitrate 1.92 -1.64 -1.23 -1.66 
pentose-P 1.30 -1.36 -1.13 -1.16 
PEP -1.46 -1.84 -1.82 -2.50 
pyruvate 1.80 1.13 1.60 4.69 
succinate -1.63 -4.55 -2.37 -6.67 
triose-P -0.98 -2.43 -1.17 -13.93 
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aconitate, (iso)citrate, pyruvate, glycine, and alanine. The metabolite extraction 
method used for this experiment could not be used to measure acetyl-CoA levels, the 
other substrate of the malate synthase reaction. Glycine, a potential downstream 
product of glyoxylate via a glyoxylate aminase reaction increased in ΔglcB in 0.2% 
acetate-containing conditions. 
In contrast to accumulations upstream of malate synthase, depletions were observed in 
downstream metabolites malate and aspartate. Malate levels were decreased in the 
knockout compared to WT 13.93-fold in 0.2% acetate and 7.15-fold in 0.2% acetate 
plus 0.2% glucose. Aspartate, which is indicative of oxaloacetate levels, was also 
decreased 4.41-fold in glucose, 9.49-fold in acetate, and 4.8-fold in 0.2% glucose plus 
0.025% acetate and 73.34-fold in 0.2% glucose plus 0.2% acetate. Other metabolite 
decreases in ΔglcB included hexose-phosphates, triose-phosphates, pentose-
phosphates, 2-methyl(iso)citrate, alanine, and succinate in 0.2% acetate-containing 
conditions. Many of these changes are absent or reduced in the 0.025% acetate plus 
0.2% glucose condition, a growth-permissive condition.   
These results indicate that upon exposure to high levels of acetate, ΔglcB experiences 
many metabolic perturbations within glycolysis/gluconeogenesis, the TCA cycle, and 
the glyoxylate shunt. Accumulations of metabolites upstream of the malate synthase 
reaction and depletion of metabolites downstream of the reaction confirm the expected 
role of glcB as the primary malate synthase gene in Mtb. These perturbations may 
contribute to the growth and survival phenotypes of ΔglcB in acetate. Interestingly, 
addition of glucose to acetate largely exacerbates the metabolic changes that we 
observe and does not improve aspartate or malate levels. Adding exogenous malate or 
aspartate did not rescue growth of ΔglcB in acetate (Figure 3.10). These data suggest 
that in Mtb lacking malate synthase, the presence of high amounts of acetate leads to  
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Figure 3.10. Exogenous malate and aspartate do not rescue acetate-mediated 
growth inhibition. (A) WT, ΔglcB, and ΔglcB complemented strains were grown in 
0.4% glucose and 0.1% acetate; 0.4% glucose; 0.4% glucose, 0.1% acetate, and 0.2% 
malate; or 0.4% glucose, 0.1% acetate, and 0.2% aspartate in carbon-defined minimal 
medium. (B) Same data as in (A) but comparing growth of WT or ΔglcB in the four 
media types used in (A).  
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accumulation of toxic metabolites (such as glyoxylate) or flux of carbon away from 
the glyoxylate shunt that leads to detrimental effects to the cell.  
3.3.8 ΔglcB accumulates metabolites in branched-chain amino acid synthesis in 
acetate 
In order to get a global picture of metabolic changes within the glcB KO exposed to 
acetate, we also identified metabolites based on their expected mass over charge ratio, 
in the absence of standards. This approach is hypothesis generating, and there is the 
possibility that metabolites are incorrectly annotated. We found that many amino acid 
pools were depleted in the glcB knockout compared to WT in 0.2% acetate and in 
0.2% acetate plus 0.2% glucose (Figure 3.11). However, metabolites involved in 
branched-chain amino acid synthesis, including α-methylmalate, α-acetolactate, and 
keto(iso)leucine were increased. This suggests that deletion of glcB affects branched 
chain amino acid synthesis and/or degradation pathways.  
A reaction that is similar to the malate synthase reaction is the first committed step of 
leucine biosynthesis catalyzed by α-isopropylmalate synthase. This reaction uses 
acetyl-CoA and α-ketoisovalerate as substrates (Koon et al., 2004). α-ketoisovaleric 
acid (C5H8O3) and glyoxylic acid (C2H2O3) are both α-keto acids, containing a 
carboxylic acid and ketone group. Due to the observed accumulation of metabolites 
upstream of this enzymatic step, we hypothesized that high glyoxylate may compete 
with α-ketoisovalerate to inhibit this reaction, or that high levels of acetyl-CoA could 
contribute to substrate inhibition. Therefore, we tried adding exogenous leucine or 
isoleucine (as a control) to rescue growth of ΔglcB. However, we did not observe a 
substantial enhancement of growth with leucine (Figure 3.12). It is possible that 
leucine does not enter Mtb efficiently enough to rescue growth, that leucine deficiency  
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Figure 3.11. Clustered heatmap of metabolite levels in the WT, ΔglcB, and ΔglcB 
complemented strains. Wild-type (WT), ΔglcB (KO), and glcB complemented 
(COMP) strains were exposed for 1 day to 0.2% glucose (Gluc), 0.2% acetate (Ace), 
0.025% acetate and 0.2% glucose (Low), or 0.2% acetate and 0.2% glucose (High) 
prior to metabolite extraction. Metabolite levels are represented as yellow 
(accumulation) or blue (depletion), as determined by the log2 value of the ion counts 
of the sample divided by the average of the ion counts of three WT samples in that 
condition. Profinder was used to analyze the data and generate ion counts while 
hierarchical complete linkage clustering by the Cluster software was used along with 
Java TreeView to organize and present the data.  
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Figure 3.12. Leucine does not rescue growth of ΔglcB in acetate. Erdman (WT) and 
ΔglcB (glcB KO) were grown in 0.2% glucose plus 0.2% acetate and incubated +/- 
0.2% leucine (leu) or 0.2% isoleucine (isoleu) (as a control).  
 
  
	  	  111 
does not contribute to acetate-mediated growth inhibition, or that other factors also 
contribute to the growth phenotype.   
Using this global analysis approach we also examined metabolic changes in 0.025% 
acetate plus 0.2% glucose, a condition in which the growth rate of ΔglcB is enhanced 
compared to 0.2% glucose alone. In general, depletions and accumulations were less 
severe in this condition compared to 0.2% acetate or 0.2% acetate plus 0.2% glucose, 
and metabolite levels were comparable to those in 0.2% glucose.  
3.3.9 Potential increase in protein acetylation in glyoxylate shunt mutants 
Although we could not measure acetyl-CoA levels in the metabolomics samples used 
for the previous analysis, we hypothesized that deleting malate synthase could result in 
enhanced levels of acetyl-CoA, or activation of pathways that use acetyl-CoA as a 
substrate. Lysine acetylation has received attention as a post-translational modification 
involved in the regulation of carbon metabolic pathways, and also uses acetyl-CoA as 
a substrate (Liu et al., 2014). Therefore, we aimed to determine whether acetylation 
profiles change in ΔglcB in 0.2% acetate, which could contribute to growth inhibition. 
We also included Δicl1Δicl2 as a control. Interestingly, we observed enhancement of 
band intensities of lysates probed with acetylated lysine antibody from both glcB and 
icl1icl2 knockouts (Figure 3.13). Future work will need to involve confirmation of the 
specificity of the antibody in detection of acetylated proteins, as adjuvants used for 
antibody generation can include Mtb components. However, this suggests that 
acetylation may occur similarly between the two knockouts in 0.2% acetate.  
3.3.10 Evidence for glyoxylate toxicity 
Glyoxylate has been implicated as a potentially toxic metabolite (Vereecke et al., 
2002). To determine whether glyoxylate toxicity plays a role in acetate-mediated  
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Figure 3.13. Global acetylation profiles of ΔglcB and Δicl1Δicl2 change in acetate. 
Erdman (WT), ΔglcB (KO), ΔglcB complemented (C) and Δicl1Δicl2 (ICL) strains 
were grown in 0.4% glucose and resuspended in 0.2% glucose or 0.2% acetate for one 
day. Protein lysates were probed using the commercially available anti-acetylated 
lysine antibody (Cell Signaling). Blot was subsequently probed with PrcB antibody as 
a loading control.   
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growth inhibition, we assessed whether adding exogenous glyoxylate could render 
ΔglcB more sensitive to acetate. A dose response assay in which growth of ΔglcB was 
measured at different acetate concentrations revealed that without glyoxylate, 0.05% 
acetate is growth inhibitory (Figure 3.14A). The presence of 0.2% or 0.3% glyoxylate 
rendered ΔglcB sensitive to 0.025% acetate. To obtain a more precise quantification of 
the inhibitory acetate concentration, we repeated this experiment with six acetate 
concentrations between 0 and 0.04% acetate (Figure 3.14B). While growth of the 
knockout was completely inhibited in 0.04% acetate, growth of the knockout plus 
0.2% glyoxylate was completely inhibited by 0.02% acetate. Although the WT 
biomass (as measured by absorbance at 580 nm) was slightly reduced with glyoxylate 
treatment, the minimum amount of acetate that inhibited growth completely (0.4%) 
did not change. This suggests that glyoxylate toxicity may contribute to acetate-
mediated toxicity. Inefficient glyoxylate entry or potential glyoxylate efflux may 
explain the absence of a more dramatic phenotype.  
More evidence supporting the idea of glyoxylate toxicity comes from the existence of 
growth conditions in which Δicl1Δicl2 grows better than ΔglcB. In media containing 
glucose or glycerol alone, ΔglcB grew better than Δicl1Δicl2 (Figure 3.5A-B), which 
is likely attributed to the dual function of icl in the methylcitrate cycle and the 
glyoxylate shunt. However, Δicl1Δicl2 grew normally on agar plates containing 10% 
OADC supplement (which contains the carbon source oleic acid) but lacking 
malachite green (not shown), whereas ΔglcB did not grow on plates containing OADC 
(Figure 3.2D) and also grew more slowly on plates lacking OADC than the icl KO. 
We investigated whether this was true for liquid culture conditions as well and found 
that ΔglcB displayed a growth lag in rich media containing 10% OADC and 0.5% 
glycerol compared to both the WT and Δicl1Δicl2 strains (Figure 3.15). This growth  
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Figure 3.14. Exogenous glyoxylate exacerbates acetate-induced growth inhibition 
of ΔglcB. (A) Sensitivity of the WT and ΔglcB to acetate in constant 0.2% glucose 
(gluc), 0.2% glucose plus 0.2% glyoxylate, or 0.2% glucose plus 0.3% glyoxylate on 
day 27. This data +/- 0.2% glyoxylate is representative of two (WT) or three (ΔglcB) 
experiments. (B) Kinetics of growth of ΔglcB in 0.2% glucose plus varied acetate 
concentrations, plus (dotted line) or minus (solid line) 0.2% glyoxylate. Data in (A) 
and (B) are means of triplicate culture +/- SEM in 96-well plates.  
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Figure 3.15. Itaconic acid rescues growth of the glcB KO in OADC. WT Erdman 
(WT), ΔglcB, the glcB complemented strain, and the Δicl1Δicl2 were grown in 7H9 
base media supplemented with 0.5% glycerol and either 10% OADC (with or without 
4 mM itaconic acid) or 10% ADNaCl.  
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lag disappeared when the supplement ADNaCl (which lacks oleic acid) was used in 
place of OADC. Importantly, addition of the isocitrate lyase inhibitor itaconic acid to 
cultures with OADC also abolished the growth lag of the glcB KO. This suggests that 
the oleic acid in OADC may enhance glyoxylate levels, which were likely reduced 
upon ICL inhibition, allowing for growth of ΔglcB.  
Although growth of ΔglcB was comparable to WT in liquid media lacking OADC, the 
time it took for colony formation on plates lacking OADC (~40 days) was 
approximately double that of the WT. To determine whether growth of ΔglcB was 
enhanced by ICL inhibition on plates, itaconic acid was added directly atop 7H10 agar 
containing 10% ADNaCl and 0.5% glycerol. This enhanced colony size of ΔglcB, 
suggesting that the beneficial effect of ICL inhibition on growth is not limited to 
OADC-containing media (Figure 3.16).  
3.3.11 Malate synthase plays a role in detoxification of odd-chain fatty acids 
Break down of long odd-chain fatty acids results in the generation of acetyl-CoA via 
β-oxidation, but also produces propionyl-CoA. Propionyl CoA-feeds into the 
methylcitrate pathway, and block of this pathway by deletion of ICL rendered Mtb 
unable to grow in propionate, even in the presence of glucose (Eoh and Rhee, 2014; 
Munoz-Elias and McKinney, 2005). Survival on 0.2% propionate was also impaired. 
Activation of an alternative propionyl-CoA metabolic pathway, the methylmalonyl 
pathway, rescued survival of the ICL-deficient strain on propionate, showing that 
buildup of propionate-derived metabolites due to methylcitrate cycle block can be 
toxic (Eoh and Rhee, 2014). Unlike ICL, MS does not play a role in the methylcitrate 
cycle pathway, so we hypothesized that ΔglcB bacteria may grow in media with 
propionate.  
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Figure 3.16. Addition of itaconic acid enhances growth of ΔglcB on solid media 
lacking OADC. ΔglcB was plated onto a 7H10 Y plate supplemented with 10% 
ADNaCl and 0.5% glycerol. Itaconic acid was added on top of the agar during plating 
in the following amounts: (A) 100ul of 246 mM (3.2%) itaconic acid, (B) 10ul of 246 
mM (3.2%) itaconic acid, or (C) no itaconic acid. The same volume of glcB culture 
was added to each section.  
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We were surprised to find that Mtb lacking glcB was unable to grow in 0.1% 
propionate (Figure 3.5C). Also, exposure to 0.1% propionate led to eventual killing of 
ΔglcB after 30 days of incubation (Figure 3.17). Furthermore, we found 0.4% glucose 
did not rescue growth of ΔglcB in 0.1% propionate or in 0.05% valerate (Figure 
3.18A,C). However, growth of ΔglcB in these conditions was improved by addition of 
10 µg/ml vitamin B12, which activates the methylmalonyl pathway by enabling 
activity of methylmaylonyl-CoA mutase (Figure 3.18B,D). In comparison with 
Δicl1Δicl2, ΔglcB had a reduced growth lag in propionate, whereas in valerate ΔglcB 
did not grow as well as Δicl1Δicl2. The Δicl1Δicl2 growth lag in 0.1% propionate can 
be explained by an accumulation of propionyl-CoA-derived metabolites to a certain 
extent despite the activation of the methylmalonyl pathway. This lag has been 
previously observed and is less pronounced or absent in 0.05% and 0.01% propionate, 
respectively (Eoh and Rhee, 2014). Perhaps in 0.05% valerate, which is converted into 
propionyl-CoA and acetyl-CoA by β-oxidation, propionyl-CoA and downstream 
metabolites accumulate to a lesser extent than in 0.1% propionate, and therefore do not 
inhibit growth of Δicl1Δicl2. Also, the growth lag of ΔglcB in valerate could be 
explained by glyoxylate toxicity coming from acetyl-CoA. These data support a role 
for malate synthase in metabolism and resistance to odd-chain fatty acids.  
We also determined whether growth of ΔglcB in acetate would be enhanced by 
activation of the methylmalonyl pathway. Addition of 10 µg/ml vitamin B12 did not 
stimulate growth of either ΔglcB or Δicl1Δicl2 in 0.2% acetate, with or without 0.2% 
glucose (Figure 3.19A-D). Previously, vitamin B12 improved growth of the Δicl1Δicl2 
in 0.2% acetate, in the presence of aspartate and glucose (Eoh and Rhee, 2014). Also, 
addition of vitamin B12 rescued survival of Δicl1Δicl2 in 0.2% acetate alone (Eoh and 
Rhee, 2014). We found that addition of vitamin B12 did not help survival of ΔglcB in  
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Figure 3.17. Propionate kills ΔglcB over time. Survival of the WT Erdman, ΔglcB, 
and ΔglcB complemented strain in no carbon compared to survival of ΔglcB in 0.1% 
propionate. The base media is carbon-defined minimal media and each data point is 
the mean +/- SD of three biological replicates.  
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Figure 3.18. Propionate and valerate inhibit growth of ΔglcB, which is rescued by 
vitamin B12. Growth of WT Erdman, ΔglcB, ΔglcB complemented, and Δicl1Δicl2 
strains in (A) 0.4% glucose and 0.1% propionate, (B) 0.4% glucose, 0.1% propionate, 
and 10 µg/ml vitamin B12, (C) 0.4% glucose and 0.05% valerate, and (D) 0.4% 
glucose, 0.05% valerate, and 10 µg/ml vitamin B12.  
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Figure 3.19. Vitamin B12 does not rescue acetate-induced toxicity. WT, ΔglcB, 
ΔglcB complemented, and Δicl1Δicl2 strains were grown in (A) 0.2% acetate, (B) in 
0.2% acetate plus 10 µg/ml vitamin B12, (C) 0.2% acetate plus 0.2% glucose, and (D) 
0.2% acetate, 0.2% glucose, and 10 µg/ml vitamin B12. (E) Survival of ΔglcB in 0.2% 
acetate with or without 0.2% glucose and 10 µg/ml vitamin B12.  
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acetate (Figure 3.19E). This suggests that activation of the methylmalonyl pathway is 
not sufficient to overcome acetate-mediated toxicity in Mtb lacking malate synthase.  
3.3.12 Mutation in gltA2 confers partial acetate resistance in Mtb lacking glcB 
As another approach to understanding acetate-mediated toxicity, we aimed to identify 
suppressor mutations that could confer resistance to acetate in the ΔglcB background. 
We plated a dense culture (~6.8 x 108 bacteria) and dilutions of ΔglcB onto plates 
containing 0.2% acetate and 0.4% glucose. Unfortunately, no colonies were obtained 
after 2.5 months of incubation.  
However, while performing growth curves with ΔglcB, we observed that in an 
intermediate amount of acetate (0.1%) plus 0.4% glucose, growth was inhibited for 
approximately twenty days, after which ΔglcB ultimately reached WT density at 
around day 35 (Figure 3.20A). To determine whether growth was due to a suppressor 
mutation, we passaged ΔglcB into identical media. While ΔglcB still had a growth lag, 
it was much reduced compared to ΔglcB strain that had never been exposed to acetate 
(Figure 3.20B). To confirm that ΔglcB had not been contaminated with a glcB 
expressing strain, we confirmed absence of MS in protein lysates harvested from the 
end of the growth curve (Figure 3.19C). We then single-colony purified this culture by 
plating, and colonies exhibited the same slow growth and small, ridged colony 
phenotype of the parent ΔglcB strain. Importantly, culture of these colonies retained 
the acetate-resistant phenotype when grown in 0.4% glucose and 0.1% acetate (Figure 
3.20D). Sequencing of the chromosomal DNA of two of these isolates in collaboration 
with Dr. Jim Sacchettini and Dr. Tom Ioerger identified a stop mutation (Y147*) in 
the gene gltA2 (Rv0896). This gene encodes a probable citrate synthase with 431 
amino acids and is similar to citA (Rv0889c), a citrate synthase (31.8% identity in 371 
aa overlap), and prpC (Rv1131 or gltA1), a methylcitrate synthase (33.1% identity in  
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Figure 3.20. Selection for an acetate-resistant ΔglcB strain. (A) Growth of the WT, 
ΔglcB, and ΔglcB complemented strains in 0.4% glucose plus 0.1% acetate in carbon-
defined minimal media. (B) Growth of cultured passaged from (A) on day 37 into the 
same media condition. (C) Western blot examining MS and PrcB expression in lysates 
harvested from (B) on day 18. (D) Growth of WT, ΔglcB (never exposed to acetate), 
and the acetate-resistant ΔglcB strain isolated from a single colony after plating of 
ΔglcB from (B) onto 7H10 ADNaCl plates.  
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381 aa overlap) according to TubercuList. Considering this potential functional 
redundancy with citA and prpC, inactivation of this gene could potentially result in 
reduced, but not abolished, citrate synthase and/or methylcitrate synthase activity 
(Figure 3.21). This suggests that the growth-inhibitory phenotype in acetate is caused 
by metabolism of carbon substrates downstream of the citrate synthase reaction.  
We tested the sensitivity of this acetate-resistant ΔglcB strain as well as the parent 
ΔglcB strain to acetate (2 carbons), propionate (3 carbons), octanoic acid (8 carbons), 
and oleic acid (18 carbons). We found that the acetate-resistant mutant was more 
resistant to acetate, propionate, octanoic acid, and oleic acid than ΔglcB, but was not 
as resistant as WT (Figure 3.22). We also determined whether addition of itaconic acid 
would help protect against acetate-mediated toxicity, considering that it should reduce 
glyoxylate buildup by blocking isocitrate lyase. However, addition of 4 mM itaconic 
acid did not shift the minimum inhibitory concentration of acetate for ΔglcB, 
suggesting that factors other than glyoxylate buildup may contribute to growth 
inhibition in this condition. These data show that in addition to acetate and propionate, 
ΔglcB growth is also sensitive to long-chain fatty acids. Also, a mutation in gltA2 
resulting in a truncated protein provided intermediate resistance to all of these fatty 
acids tested. More work is needed to confirm the function of gltA2 and to confirm that 
loss of gltA2 alters metabolic flux downstream of citrate synthase. 
3.4 Discussion 
Data reported here promotes malate synthase (MS) as a drug target and reveals fatty 
acid sensitivity in MS-deficient Mtb. We found that glcB, the gene encoding MS in 
Mtb, was essential for establishment and maintenance of infection in the mouse and 
that it was required for growth and survival of Mtb in high levels of acetate. Acetate, 
similar to long-chain fatty acids, is converted to acetyl-CoA for entrance into the TCA  
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Figure 3.21. Potential roles of gltA2 in the methylcitrate and TCA cycles. The 
gene gltA2 is annotated as a probable citrate synthase in the H37Rv Mtb genome and 
has 33.1% identity with the citrate synthase citA and 31.8% identity with the 
methylcitrate synthase prpC. 
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Figure 3.22. The acetate-resistant ΔglcB strain is also more resistant to other 
fatty acids compared to the ΔglcB strain. Sensitivity of the WT, ΔglcB, and acetate-
resistant (ace-R) ΔglcB strains (with a truncated gltA2) to (A) acetate plus or minus 
4mM itaconic acid, (B) propionate, (C) octanoic acid, and (D) oleic acid on day 28. 
Variable carbon source was added to carbon-defined minimal media with 10% 
ADNaCl (for a final concentration of 0.5% fatty acid-free bovine serum albumin, 
0.2% glucose, and 0.085% sodium chloride) in 96-well plate format. Data are means 
+/- SEM of triplicate wells.    
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cycle and the glyoxylate shunt. Also, glcB was required for growth in cholesterol, a 
physiologically relevant carbon source that is degraded into a mixture of acetyl-CoA, 
propionyl-CoA, and pyruvate. Unexpectedly, we found that glucose did not rescue 
growth or survival of the glcB knockout strain (ΔglcB) in high acetate concentrations. 
This suggests that the presence of glycolytic carbon sources in the host environment 
may not overcome fatty acid toxicity in the absence of MS. As evidence suggests that 
the host provides Mtb with fatty acids and other lipids, it is possible that these 
contribute to the killing we observe upon MS depletion in vivo. This promotes further 
work on MS inhibitors as an antibacterial strategy.  
Why is Mtb lacking MS impaired for growth and survival by the presence of carbon 
sources that enter carbon metabolism as acetyl-CoA? And why would glucose 
exacerbate this phenotype rather than lead to rescue? We first wanted to investigate 
whether accumulation of a toxic metabolite could contribute to this phenotype. Two 
metabolites likely to accumulate in ΔglcB are acetyl-CoA and glyoxylate, the 
substrates of the MS reaction. While it was not possible to measure acetyl-CoA levels 
using the metabolite preparation protocol we used, we were able to detect elevated 
glyoxylate levels in ΔglcB compared to the wildtype and complemented strains in 
glucose, acetate, and combinations of glucose and acetate. Glyoxylate accumulations 
were highest in 0.2% acetate and 0.2% acetate plus 0.2% glucose, and higher 
glyoxylate levels correlated with a greater extent of killing. Furthermore, glyoxylate 
accumulated the most out of any metabolite we examined in relation to WT pool sizes 
in these conditions. Therefore, glyoxylate buildup was linked with growth inhibition 
and death of ΔglcB. 
Is glyoxylate buildup toxic for Mtb? Glyoxylate toxicity has been proposed as a reason 
for the pathogenicity defect of a Rhodococcus fascians strain with a mutation in MS 
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(Vereecke et al., 2002). Glyoxylate may be toxic for several reasons. Glyoxylate exists 
primarily as a gem-diol hydrate in which one carbon is bonded with two hydroxyl 
groups, but can also exist in a reactive form containing an aldehyde group (Jiang et al., 
2012).  This can potentially react with proteins or DNA within the cell, causing 
damage. Also, glyoxylate can act as a metabolic regulator in several ways. Glyoxylate 
can compete with structurally similar metabolites for the active sites of metabolic 
enzymes, as has been demonstrated in its ability to compete with pyruvate and inhibit 
pyruvate dehydrogenase (Beatty and Hamilton, 1985; Dangelmaier and Holmsen, 
2014). Glyoxylate can also condense with metabolites such as oxaloacetate and 
pyruvate, and those products can act as regulators to inhibit enzymes like isocitrate 
dehydrogenase, α-ketoglutarate dehydrogenase, or aconitase (El-Mansi et al., 1986; 
Ruffo et al., 1967; Yushok, 1971). Finally, abundance of glyoxylate may activate or 
inhibit enzymes whose reaction involves glyoxylate as a substrate or product, such as 
isocitrate lyase (ICL), alanine dehydrogenase (ALD, which has glyoxylate reductive 
aminase activity), or 2-hydroxy-3-oxoadipate synthase (HOAS). Glyoxylate 
accumulation can therefore be problematic for the cell by many potential mechanisms.  
To investigate this glyoxylate toxicity hypothesis, we determined whether adding 
exogenous glyoxylate increased sensitivity of ΔglcB to acetate. We found that 
glyoxylate prevented growth of ΔglcB in 0.02% acetate, whereas 0.04% acetate was 
required to prevent growth without glyoxylate. This slight shift in acetate sensitivity 
suggests that glyoxylate may contribute to toxicity, but inefficient uptake or efficient 
efflux of glyoxylate may have prevented the phenotype from being more extreme.  
We also observed phenotypic differences between the isocitrate lyase and MS-
deficient bacteria that supported the glyoxylate toxicity hypothesis. While both strains 
are similarly inhibited for growth in 0.2% acetate in liquid media, Δicl1icl2 grows 
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much better than ΔglcB in liquid media with OADC. OADC contains oleic acid, 
which can be catabolized into acetyl-CoA to enter into the TCA cycle. It is possible 
that bacteria growing on 0.006% oleic acid do not generate acetyl-CoA as efficiently 
as during growth on 0.2% acetate, but that this lower amount of acetyl-CoA is 
sufficient to contribute to glyoxylate toxicity. Adding OADC to solid media also 
prevented growth of the ΔglcB but not Δicl1icl2. This suggested that growth inhibition 
of the ΔglcB in the presence of oleic acid could be caused by a metabolite buildup that 
did not occur in Δicl1Δicl2 bacteria, such as glyoxylate buildup.  
We aimed to determine whether reducing glyoxylate accumulation in ΔglcB would 
enhance growth in media containing OADC. We found that addition of the ICL 
inhibitor itaconic acid restored growth of ΔglcB in OADC to WT levels. Future work 
using metabolomics to assess the intracellular levels of glyoxylate and other 
metabolites in conditions with OADC in the presence and absence of itaconic acid 
could provide further evidence for this glyoxylate toxicity hypothesis. Also, 
overexpressing enzymes such as ALD (glyoxylate + NADH à glycine + NAD+) or 
HOAS (glyoxylate + α-ketoglutarate à 2-hydroxy-3-oxoadipate) could drain 
glyoxylate levels and rescue growth of ΔglcB in OADC if glyoxylate toxicity is the 
culprit (de Carvalho et al., 2010b; Giffin et al., 2012). However, in lieu of these 
experiments, glyoxylate toxicity remains the most straightforward explanation for the 
growth inhibition of ΔglcB in OADC. 
Surprisingly, addition of itaconic acid to plate media lacking OADC also enhanced 
growth of the ΔglcB strain, suggesting that glyoxylate toxicity also occurs on plates in 
the absence of oleic acid. Is it possible that itaconic acid enhances growth via a 
mechanism other than glyoxylate buildup prevention? Macrophages are known to 
secrete itaconic acid as a defense mechanism and as a response, intracellular 
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pathogens have evolved itaconic acid degradation pathways (Michelucci et al., 2013; 
Sasikaran et al., 2014). In Yersinia pestis and Pseudomonas aeroginosa, itaconic acid 
break-down results in the production of succinate, pyruvate, and acetyl-CoA 
(Sasikaran et al., 2014). It is possible that Mtb also encodes such pathways and uses 
them to generate these metabolites, which could potentially act as carbon sources and 
contribute to growth. However, considering that addition of itaconic acid does not 
enhance growth of Δicl1Δicl2, it seems unlikely that itaconic acid promotes growth 
due to this reason. It seems more likely that low levels of glyoxylate produced in 
plates lacking OADC is sufficient to slow down, but not abolish growth of ΔglcB. 
Is acetyl-CoA buildup toxic? Acetyl-CoA is a substrate for acetylation, participates in 
fatty acid and amino acid biosynthesis, and acts as an allosteric regulator of several 
metabolic enzymes. By western blot, we detected higher reactivity with the acetylated 
lysine antibody when we probed ΔglcB lysate but not WT lysate after cells were 
exposed for one day to acetate. However, we observed similar levels of reactivity with 
proteins of the same sizes in Δicl1Δicl2, suggesting that enhanced acetylation is not 
specific to ΔglcB and may not explain the differences we observe between the two 
knockouts. Future work will need to confirm the specificity of the acetylated lysine 
antibody to acetylated proteins. Incubation of acetylated lysine antibodies with known 
acetylated proteins prior to use should result in reduced band intensities in a blot with 
Mtb lysates. Following this confirmation, it would be of interest to determine whether 
acetylation in ΔglcB occurs in other fatty acids, and does not occur in 0.025% acetate 
plus 0.2% glucose, to better link the occurrence of acetylation with growth inhibition. 
This could be followed with purification and identification of acetylated proteins that 
are present in all growth inhibitory conditions. An alternative experiment would be to 
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overexpress a deacetylase in ΔglcB to see whether reducing acetylation rescues growth 
in 0.2% acetate.  
However, identification of a mutation in the ΔglcB background that enhances acetate 
resistance provided evidence against the acetyl-CoA toxicity hypothesis. This is 
because the loss-of-function mutation is in gltA2, a gene that encodes a probable 
citrate synthase. Loss of this function would likely exacerbate acetyl-CoA 
accumulation while slowing down accumulation of downstream metabolites. This 
suggests that whatever metabolic activity that causes growth inhibition is downstream 
of the citrate synthase reaction, and that acetyl-CoA buildup may not be the cause of 
toxicity. It may be interesting to further investigate whether acetylation profiles in 
acetate-resistant ΔglcB strain are enhanced due to citrate synthase inhibition, arguing 
against a role for acetylation-induced toxicity.  
In addition to altered levels of substrate and products of the MS reaction, we observed 
other metabolic changes in ΔglcB. We observed accumulation of glycine and α-
ketoglutarate in conditions with acetate (and in glucose for α-ketoglutarate). Levels of 
glyoxylate and α-ketoglutarate were especially high in 0.2% glucose + 0.2% acetate. 
Conversely, we observed a reduction in aspartate in all conditions tested, showing that 
0.2% glucose is not sufficient to maintain aspartate levels. We also observed a 
reduction in succinate and fumarate in conditions with 0.2% acetate. It was previously 
noted that there was a partial bifurcation of the TCA cycle between α-ketoglutarate 
and succinate as determined by disparate pool sizes and carbon flux, despite existing 
enzymatic reactions that link the two metabolites (de Carvalho et al., 2010a). However, 
ICL should be able to generate succinate, and the succinate depletion we observe 
remains unexplained. We also observed increases in branched chain amino acid 
pathway metabolites, which could be linked to acetyl-CoA or glyoxylate accumulation. 
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For example, the α-isopropylmalate synthase reaction is the first step of leucine 
synthesis and uses acetyl-CoA as a substrate (Koon et al., 2004). However, the reasons 
for these accumulations remain to be clearly defined. It is possible that these metabolic 
changes contribute to the death phenotype that we observe in 0.2% acetate.  
While there are differences in the growth phenotypes of ΔglcB and Δicl1Δicl2 in 
OADC, growth of both knockouts is inhibited by 0.2% acetate (Eoh and Rhee, 2014). 
It is probable that a combination of similar and contrasting mechanisms contribute to 
the phenotypes of these knockouts in this condition. For example, starvation induced 
by blockage of the glyoxylate shunt, channeling of carbon away from the glyoxylate 
shunt and into the TCA cycle, and mutant-specific factors (glyoxylate accumulation or 
methylcitrate cycle block) could all contribute. It may be interesting to test whether 
blockage of the glyoxylate shunt lead to alterations in NAD+/NADH ratio, ATP 
generation, and/or redox balance. Enhanced antibiotic sensitivity of Δicl1Δicl2 was 
alleviated by addition of antioxidants, suggesting that Δicl1Δicl2 is either more 
susceptible to oxidative stress or generates more reactive oxygen species than WT 
during antibiotic treatment (Nandakumar et al., 2014). Mtb under anaerobic conditions 
was shown to upregulate both isocitrate lyase and glycine dehydrogenase (which can 
perform the reductive amination of glyoxylate and convert NADH to NAD+). 
Therefore, deletion of ICL may have a more dramatic effect on redox balance than an 
MS deletion. It will be of interest to determine whether addition of an antioxidant such 
as thiourea could rescue growth or survival in acetate for both knockouts. If so, this 
would support a role for the glyoxylate shunt in minimizing oxidative stress.  
We found that acetate-mediated growth inhibition is a concentration-dependent 
phenotype. Despite inhibiting growth at high concentrations, low concentrations of 
acetate (0.025%) helped growth of ΔglcB in the presence of glucose, similarly to WT. 
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Metabolomics analysis showed that at 0.025% acetate plus 0.2% glucose, many of the 
metabolic changes observed in 0.2% acetate were absent or less severe. Therefore, the 
glyoxylate shunt is not required for co-catabolism of acetate and glucose at low acetate 
concentrations. 
Growth inhibition of ΔglcB mediated by fatty acids is not limited to even-chain fatty 
acids. We observe that ΔglcB is inhibited by 0.1% propionate (3 carbons) and 0.05% 
valerate (5 carbons), whereas the WT is not. This differs from a M. smegmatis mutant 
lacking glcb and gcl (involved in the D-glycerate pathway, an alternative glyoxylate 
metabolic pathway), which did not have problems growing on propionate. 
Interestingly, activation of an alternative propionyl-CoA metabolic pathway (the 
methylmalonyl pathway) alleviated growth inhibition for the Mtb glcB knockout. This 
was unexpected, because unlike Δicl1Δicl2, ΔglcB should have a functional 
methylcitrate pathway to detoxify propionyl-CoA-derived metabolites. Indeed, we 
observe depletions, rather than accumulations, of methyl(iso)citrate in ΔglcB in acetate, 
suggesting that there is no block of the methylcitrate pathway as is observed in 
Δicl1Δicl2. However, these growth phenotypes in odd-chain fatty acids could be 
attributed to depletion of oxaloacetate, which feeds into the methylcitrate pathway. 
While we cannot measure oxaloacetate levels, we observe a depletion of aspartate, 
whose levels are an indication of oxaloacetate. We also observe a depletion of malate, 
which directly contributes to oxaloacetate generation by the enzymatic activity of 
malate dehydrogenase. Perhaps propionyl-CoA itself is toxic and cannot be drained 
via the methylcitrate cycle during a paucity of oxaloacetate caused by MS deletion.  
It is puzzling why a truncation in the probable citrate synthase gltA2 can augment 
growth of ΔglcB in propionate. It is possible that gltA2 can also function as a 
methylcitrate synthase. Salmonella enterica expresses a citrate synthase encoded by 
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gltA, that has 53% amino acid identity and 70% amino acid positives compared to the 
Mtb H37Rv gltA2 by NCBI BLAST analysis. The S. enterica gltA has been shown to 
function as a methylcitrate synthase, generating isomers of methylcitrate that vary 
from those produced by the methylcitrate synthase PrpC and are potentially more 
difficult to be metabolized by the downstream enzyme, methylcitrate dehydratase 
(Rocco and Escalante-Semerena, 2010). These isoforms could contribute to toxicity. It 
is possible that something similar occurs in Mtb. It would be of interest to see what 
effect depletion of this enzyme in combination with MS depletion has on TCA cycle 
and methylcitrate cycle metabolite levels in Mtb in propionate. 
Does Mtb alter its metabolism in response to acetate? It is possible that high levels of 
acetate trigger metabolic regulation that exacerbates the effect of glyoxylate shunt 
deletion. In E. coli, acetate activates the glyoxylate shunt by triggering 
phosphorylation of isocitrate dehydrogenase (ICDH) by the kinase AceK, which 
inhibits ICDH and redirects carbon flow through the glyoxylate shunt (El-Mansi et al., 
1986; Quartararo et al., 2013). Mtb lacks a homolog for AceK and the ICDH of Mtb 
has no identified phosphorylation sites, suggesting an alternative regulatory 
mechanism (Quartararo et al., 2013). However, transcriptional regulation in response 
to carbon source is known to occur in Mtb. RamB (encoded by rv0465c) is a 
transcriptional regulator that reduces the expression of icl1 in glucose, and can also 
bind its own promoter region (Micklinghoff et al., 2009). RamB is expressed in both 
acetate and glucose; therefore in acetate other mechanisms must exist to prevent 
inactivation of icl1 by RamB.  
The post-translational protein modification of lysine acetylation has gained much 
attention as a mechanism by which metabolic pathways are regulated in bacteria, and 
is known to occur in Mtb (Liu et al., 2014). Mtb Acetyl-CoA synthetatse (ACS), the 
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enzyme that converts acetate to acetyl-CoA and propionate to propionyl-CoA, is 
inhibited by lysine acetylation (Xu et al., 2011). It is possible that the potential 
changes in acetylation that we observed in Mtb lacking a functional glyoxylate shunt 
in response to acetate, alter carbon flux in Mtb. This could also have an effect on 
propionate metabolism, or other metabolic pathways (Liu et al., 2014; Nambi et al., 
2013).   
In conclusion, these data outline a role for glcB as the sole malate synthase in Mtb, 
whose function is required for growth and survival in high levels of acetate and in the 
mouse model of tuberculosis. However, glcB is not essential for growth in glucose or 
glycerol as a sole carbon source, showing that glcB essentiality is carbon-source 
dependent. The question remains, why is glcB required in the mouse model? It is 
plausible that the sensitivity of ΔglcB to fatty acids (caused by glyoxylate toxicity, 
blockage of the glyoxylate shunt, or alternative mechanisms) found in the host 
environment contributes to the in vivo phenotype. This does not rule out a role for 
glcB in response to other host stresses. Considering the many roles of ICL in Mtb 
pathogenesis in different stress conditions, it would be of interest to determine whether 
the same sensitivities occur in Mtb lacking MS. However, considering that fatty acids 
and other lipids are likely accessible to Mtb in the human, they may be sufficient to 
induce Mtb death in humans treated with potent MS inhibitors, supporting further 
work on MS inhibitor development. 
3.5 Materials and Methods 
3.5.1 Ethics statement 
Animal experiments were performed as according to National Institutes of Health 
guidelines for housing and care of laboratory animals. The Institutional Animal Care 
and Use Committee of Weill Cornell Medical College evaluated and approved the 
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protocol #0601-441A, Conditional Expression of Mycobacterial Genes, which we 
followed during these experiments.  
3.5.2 Bacterial culture conditions 
For standard liquid Mtb media, Middlebrook 7H9 with 10% homemade ADNaCl 
(final concentration of 0.5% bovine serum albumin (BSA) fraction V, 0.2% glucose, 
0.085% NaCl), 0.2% glycerol, and 0.05% tyloxapol was used. For standard Mtb plate 
media, Middlebrook 7H10 with 10% commercial OADC supplement (final 
concentration 0.5% bovine serum albumin, 0.2% glucose, 0.085% NaCl, 0.006% oleic 
acid, and 0.0003% catalase) and 0.5% glycerol was used, prepared according to 
manufacturers instructions. However, in any experiment involving the confirmed 
ΔglcB strain, 10% ADNaCl (made with Roche BSA fraction V, heat shock, fatty acid-
free with total FA≤1.2 mg/g) was used instead of OADC in plate media and instead of 
regular ADNaCl in liquid media. Carbon-defined media was composed of 0.05% 
potassium phosphate monobasic, 0.05% magnesium sulfate heptahydrate, 0.2% citric 
acid, 0.005% ferric ammonium sulfate, 0.05% ammonium sulfate, 0.0001% zinc 
sulfate, and 0.05% tyloxapol. Carbon sources propionic acid, butyric acid, sodium 
acetate, valeric acid, octanoic acid, oleic acid, aspartic acid, malic acid, glucose, and 
glycerol were added at the indicated concentration (%wt/vol or %vol/vol, depending 
on stock), and pH adjusted to 7.4. Growth curves with cholesterol were performed in 
“Sassetti base media” according to the protocol from Griffin et. al. 2012. Briefly, a 
500x stock of cholesterol was made by addition of 100mg cholesterol to 1 ml of 
tyloxapol and 1 ml of ethanol. This was heated to 95°C-100°C before addition to 
minimal media containing 0.5 g/L asparagine, 1 g/L KH2PO4, 2.5 g/L Na2HPO4, 0.05 
g/L ferric ammonium citrate, 0.5 g/L MgSO47H2O, 0.5 mg/L CaCl2, and 0.1 mg/L 
ZnSO4. Media was sterile filtered before addition of bacteria. Optical density (OD) 
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measurements taken with vitamin B12 or cholesterol-containing media required an 
appropriate blank to account for color or cloudiness. When required, antibiotics 
hygromycin B (50 µg/ml), streptomycin (10 µg/ml), kanamycin (25 µg/ml) and/or 
zeocin (25 µg/ml) were added. Where indicated, anhydrotetracycline (atc) was added 
at 500ng/ml and replenished at 250 ng/ml every 4-5 days. For metabolomics profiling, 
Mtb culture at OD580~1 was seeded onto 0.22 µM nitrocellulose filters atop 7H10 agar 
plates containing 0.2% glucose and 0.5% glycerol for 4 days, then 0.2% glucose for 2 
days, before transfer to the indicated carbon source for 1 day. Bacteria were 
subsequently quenched in cold acetonitrile:methanol:water (40:40:20) buffer, scraped 
off of filters, and mechanically lysed using a beadbeater prior to metabolite analysis.  
3.5.3 Generation of mutant strains 
All mutant strains generated and evaluated in this chapter were generated in the 
Mycobacterium tuberculosis Erdman background. To generate the glcB mutant strains, 
Mtb was first transformed with an attL5-integrating plasmid expressing under the 
control of its native promoter. This merodiploid strain was then transformed with a 
temperature-sensitive knockout plasmid containing a hygromycin resistance cassette 
flanked with regions homologous to those surrounding glcB in the Mtb genome. This 
plasmid was designed to remove all of glcB except for the last 86 base pairs. This 
plasmid also expressed xylE and sacB in the backbone, which aided in selection of 
knockout candidates. xylE expression results in colonies turning yellow upon exposure 
to catechol, and sacB confers sucrose sensitivity. After confirming successful 
transformation with the knockout plasmid by addition of catechol, we grew up and 
plated this strain on plates containing sucrose at 40°C to select for double crossover 
events. A double crossover results in the removal of the backbone of the plasmid but 
retention of the hygromycin resistance cassette in place of the glcB gene. After 39 
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days, a few colonies were obtained, which we propagated and obtained DNA to 
confirm the lack of native glcB by PCR and Southern blot. This att-site mutant strain 
was then used to generate both the glcB-DUC and glcB knockout strains. To generate 
glcB-DUC, the att site mutant was transformed with an att-site-integrating plasmid 
expressing glcB C-terminally tagged with DAS+4 under the control of a Tet-OFF 
promoter (p750) controlled by the tet repressor T38S38, and also a tweety-site 
integrating plasmid expressing sspB under the control of a Tet-ON promoter (P1) 
controlled by TSC10M repressor as described (Ehrt et al., 2005; Kim et al., 2013). The 
glcB knockout strain (ΔglcB) was generated from the att site mutant by replacement 
transformation of the glcB-expressing plasmid in the attL5 site with a plasmid lacking 
glcB. The glcB complemented strain was generated by transforming ΔglcB with an 
attL5-site integrating plasmid expressing glcB under the control of the native glcB 
promoter. Gateway Cloning technology (Invitrogen) was used to generate all plasmids 
in this study, via BP and LR recombinase, as instructed by the manufacturer.  
3.5.4 Metabolomics 
Liquid chromatography mass spectrometry differentiation and detection of Mtb 
metabolites was performed with an Agilent Accurate Mass 6220 TOF coupled with an 
Agilent 1200 Liquid Chromatography system using a Cogent Diamond Hydride Type 
C column (Microsolve Technologies) as described (Eoh and Rhee, 2013). Standards of 
authentic chemicals of known amounts were mixed with bacterial lysates and analyzed 
to generate the standard curves used to quantify metabolite levels. These were 
normalized to lysate protein levels, which were quantified using a BCA Protein Assay 
Kit (Pierce). Data was analyzed using Profinder B.06.00 software. The clustered 
metabolite heatmap was generated with Gene Cluster 3.0 and Java TreeView 1.1.6r3 
software.  
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3.5.5 Mouse infection 
Female C57BL/6 mice (Jackson Laboratory) were exposed to aerosolized Mtb using a 
Glas-Col inhalation exposure system. 5 ml of OD 0.2 Mtb single-cell suspension in 
PBS was injected into the nebulizer to deliver 100 to 200 bacilli per mouse. At the 
indicated time-points, doxycycline food (2000ppm, Research Diets) was administered 
in lieu of regular mouse chow for the rest of the experiment. To quantify bacteria, 
dilutions of lung and spleen homogenates were plated onto 7H10 plates containing 
10% ADNaCl (fatty acid-free BSA) and 0.5% glycerol for CFU.  
3.5.6 Antibody generation and western blotting 
Recombinant malate synthase protein (made from overexpression of Mtb glcB) was 
obtained from the Sacchettini Lab at Texas A&M. Rabbit polyclonal antibodies 
specific for this protein were generated by GenScript. For western blotting, protein 
lysates were prepared from Mtb cells by mechanical lysis 2x at 4,500RPM for 30 
seconds with 0.1mm zirconia/silica beads. Bacterial cell wall components and beads 
were removed via centrifugation and filtration using 0.2 µm spin-X columns (Corning). 
Protein quantification was assessed using a DC-Protein Assay Kit (Bio-Rad). Protein 
lysates were separated using SDS-PAGE and transferred to a nitrocellulose membrane, 
which was incubated with Odyssey blocking buffer and PBS (1:1). Membrane was cut 
between 30 and 80 kDa and incubated with either malate synthase antibody (1:3,500) 
or PrcB (1:20,000) antibody in Odyssey blocking buffer and PBS (1:1) in 0.1% 
Tween-20. The membranes were washed and then incubated with secondary IRDye 
680 Donkey anti-Rabbit IgG (H+L) (LI-COR Biosciences). After washing, proteins 
were visualized using Odyssey Infrared Imaging System (LI-COR Biosciences). For 
analysis of acetylated proteins, 80ml Mtb strains were grown in roller bottles at 37C in 
minimal media containing 0.4% glucose until they reached OD~1. Strains were then 
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centrifuged to remove media and resuspended in minimal media containing 0.2% 
acetate or 0.2% glucose. After 24 hour incubation, lysates were prepared and used for 
western blotting as just described. For primary antibody, acetylated lysine antibody 
(Cell Signaling) was used at a dilution of 1:2,500, followed by secondary at 1:15,000. 
3.5.7 Survival assays 
Mtb cultures were grown to OD 0.2-1 in 7H9 with 10% ADNaCl (made with fatty 
acid-free BSA) and spun down to remove the media. Pellets were resuspended in 
carbon-defined minimal media and used to inoculate 10 mls of the media of interest at 
an OD of 0.01. Cultures were incubated at 37°C at 5% CO2 in T25 vented flasks. 
Flasks were shaken to resuspend bacteria before aliquots were taken for serial 
dilutions and plating onto 7H10 plates containing 10% ADNaCl (fatty acid-free BSA) 
and 0.5% glycerol.  
3.5.8 Genome sequencing 
Genomic DNA was prepared from Mtb cultures ~OD 1 by phenol:chloroform 
extraction. Genomic DNA was sequenced by the Sacchettini Lab at Texas A&M and 
data analyzed by Dr. Tom Ioerger.  
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CHAPTER 4 
CONCLUDING REMARKS 
 
Carbon metabolic pathways are becoming well recognized for their roles in Mtb 
pathogenesis. Here, we evaluated the importance of two enzymes in separate 
pathways; fructose 1,6-bisphosphate aldolase (FBA) in glycolysis and 
gluconeogenesis, and malate synthase (MS) in the glyoxylate shunt. We found that 
both were essential for growth and persistence of Mtb in the mouse model, supporting 
their further pursuit as potential drug targets. This further exemplifies the importance 
of Mtb carbon metabolic pathways during host infection.  
This work would not have been possible without the development of conditional 
knockdown mutants. The dual control system developed by Kim and O’Brien et al.  
allowed us to generate Mtb mutants in which both gene expression and protein 
stability of FBA and MS were regulated by the addition of anhydrotetracycline or 
doxycycline. These mutants were generated in conditions in which these enzymes 
were essential but then used to test the effect of FBA and MS depletion in the mouse 
model and within a variety of in vitro conditions. In doing so, we found a condition in 
which both FBA and MS were dispensable: standard Mtb media containing glucose 
and glycerol, but lacking oleic acid. We also found that the essentiality of both 
enzymes was carbon source-dependent.  
Why is identification of condition-specific essentiality important? First of all, this 
demonstrates how gene essentiality studies based on detecting transposon insertions 
within Mtb libraries can be contradictory. Both of the genes of interest, fba and glcB, 
were predicted to be essential and non-essential, depending on the study (Griffin et al., 
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2011; Sassetti et al., 2003; Zhang et al., 2012). Our data suggested that this variability 
could be due to the differences in the growth media used to perform these experiments. 
Also, this work highlights the importance of targeted genetic studies to validate gene 
essentiality predictions.  
Secondly, when testing enzyme inhibitors against live bacteria, it is critical to test in a 
condition where the enzyme is required for growth or viability. We found that growth 
of both fba and glcB knockouts was similar to wild type in standard liquid Mtb media. 
This was unexpected due to the inability to generate knockouts for these enzymes on 
standard Mtb plate media. We confirmed that FBA is essential in single carbon source 
media and that MS is essential in the presence of acetate or fatty acids, suggesting that 
inhibitor testing should be done in these conditions. Standard media may be a good 
control to identify off-target inhibitor effects.  
Lastly, this carbon source-dependent essentiality provides one hypothesis for the 
phenotype we observe in vivo, and contributes to our understanding of the host 
environment. We found that FBA is required for growth and survival in single carbon 
sources, and that an fba knockout requires a specific balance of carbon sources for 
growth. In contrast, MS is required for growth and survival in acetate, regardless of 
the presence of glucose. If carbon source contributes to death of these mutants in vivo, 
these data are consistent with the current paradigm of an Mtb diet high in lipids, 
including fatty acids, and low in other carbon sources such as carbohydrates.  
Why are both mutants killed by carbon as opposed to just inhibited for growth? We 
used a metabolomics LC-MS-based approach to determine the metabolic changes of 
the knockouts upon exposure to carbon sources that were permissive and non-
permissive for survival.  We observed large metabolite accumulations in both 
knockouts consistent with their established functions. Metabolite toxicity of 
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glyoxylate (for MS-deficient Mtb) or phosphorylated metabolites surrounding the FBA 
reaction (for FBA-deficient Mtb) could contribute to the death that we observe. 
However, metabolic pathways also have other roles in maintenance of redox balance, 
membrane potential, and cell wall synthesis, altering the lipid profile. Further studies 
are needed to elucidate the specific mechanisms accounting for the death we observe.  
Carbon source may not be the only cause of death of strains lacking MS or FBA in 
vivo, as FBA or MS could contribute to resistance of Mtb to other host stresses. For 
example, hypoxia has been shown to trigger a reductive TCA cycle with an output of 
succinate, whose production contributes to Mtb survival (Eoh and Rhee, 2013; 
Watanabe et al., 2011). Also, both FBA and MS are known to be secreted and could 
play roles in altering the host environment in a way that favors Mtb survival within the 
host (Kinhikar et al., 2006; de la Paz Santangelo et al., 2011). Future work could 
involve mutation of either the active site or potential host-interacting domains within 
these proteins to see what effect this has on pathogenicity within the host.   
How feasible would it be to develop inhibitors to target FBA and MS? The crystal 
structures of both enzymes are available, allowing for structure-based drug design. 
Development of inhibitors for both enzymes is currently ongoing in other institutions. 
Progress is furthest on MS inhibitors, which have been shown to reduce bacillary load 
in vivo (Krieger et al., 2012). MS may be easier to target compared to isocitrate lyase 
(ICL) because of its accessible active site.  
FBA inhibitors have been generally ineffective at inhibiting Mtb growth in vitro 
against live bacteria, and one of the issues could be a lack of potency. To determine 
the potency required for an FBA inhibitor, we assessed the vulnerability of Mtb to 
FBA depletion and found that FBA needed to be depleted over 97% in butyrate to 
have an effect on growth. This mimics the findings of a study with the fungus Candida 
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albicans, in which FBA expression needed to be silenced over 95% to block growth 
(Rodaki et al., 2006). Interestingly, we found that vulnerability was dependent on the 
growth condition, as in glucose FBA needed to be depleted by only 87% to have an 
effect on growth. This suggests that it may be difficult to predict the level of depletion 
required in various environments, including the host. Also, there are examples of 
effective antibiotics whose targets require high levels of depletion (Wei et al., 2011). 
These data suggest that while FBA may need to be inhibited substantially for an effect 
in vivo, FBA should not be ruled out as a drug target.  
In conclusion, we have outlined a critical role for both MS and FBA for Mtb 
pathogenesis. Depletion of either enzyme after establishment of infection in mice 
resulted in drastic declines in bacterial load over time in lungs and spleens. Both 
enzymes were also required for in vitro survival in specific carbon source conditions 
that may mimic the carbon source condition in vivo. Moreover, Mtb lacking either 
enzyme exhibited metabolic buildups and depletions in death-inducing carbon source 
conditions. It is possible that these metabolic perturbations contributed to the death 
that we observed in vitro, and potentially in the mouse model. This work justifies 
continued research on the importance and function of carbon metabolism enzymes in 
Mtb and the development of novel inhibitors targeting FBA and MS.   
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